10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

[X]	Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
	For the quarterly period ended September 30, 2016
[  ]	Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934
	For the transition period from __________  to __________
	Commission File Number: 000-25911

Skinvisible, Inc.

(Exact name of Registrant as specified in its charter)

Nevada	88-0344219
(State or other jurisdiction of incorporation or organization)	(IRS Employer Identification No.)

6320 South Sandhill Road, Suite 10, Las Vegas, NV 89120

(Address of principal executive offices)

702.433.7154

(Registrant’s telephone number)

 _______________________________________________________________

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days

[X] Yes [ ] No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.

[  ] Large accelerated filer	[  ] Accelerated filer
[  ] Non-accelerated filer	[X] Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

[ ] Yes [X] No

State the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 123,835,319 common shares as of November 2, 2016

1

	TABLE OF CONTENTS	Page
PART I – FINANCIAL INFORMATION
Item 1:	Financial Statements	3
Item 2:	Management’s Discussion and Analysis of Financial Condition and Results of Operations	4
Item 3:	Quantitative and Qualitative Disclosures About Market Risk	11
Item 4:	Controls and Procedures	11
PART II – OTHER INFORMATION
Item 1:	Legal Proceedings	12
Item 2:	Unregistered Sales of Equity Securities and Use of Proceeds	12
Item 3:	Defaults Upon Senior Securities	13
Item 4:	Mine Safety Disclosure	13
Item 5:	Other Information	13
Item 6:	Exhibits	14

2

PART I - FINANCIAL INFORMATION

Item 1.     Financial Statements

Our consolidated financial statements included in this Form 10-Q are as follows:

F-1   Consolidated Balance Sheets as of September 30, 2016 and December 31, 2015 (unaudited);

F-2   Consolidated Statements of Operations for the three and nine months ended September 30, 2016 and 2015 (unaudited);

F-3   Consolidated Statements of Cash Flow for the nine months ended September 30, 2016 and 2015 (unaudited);

F-4   Notes to Consolidated Financial Statements.

These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and the SEC instructions to Form 10-Q.  In the opinion of management, all adjustments considered necessary for a fair presentation have been included.  Operating results for the interim period ended September 30, 2016 are not necessarily indicative of the results that can be expected for the full year.

3

SKINVISIBLE, INC.

CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

	September 30, 2016			December 31, 2015
ASSETS
Current assets
Cash	$	—		$	—
Accounts receivable		7,723			5,000
Inventory		81,752			90,972
Due from related party		1,145			1,145
Prepaid expense and other current assets		—			—
Total current assets		90,620			97,117
Fixed assets, net of accumulated depreciation of $326,786 and $325,855, respectively		764			1,695
Intangible and other assets:
Patents and trademarks, net of accumulated amortization of $386,851 and $344,451, respectively		259,318			301,718
Total assets	$	350,702		$	400,530
LIABILITIES AND STOCKHOLDERS' DEFICIT
Current liabilities
Accounts payable and accrued liabilities	$	934,720		$	529,245
Bank overdraw		2,886			1,340
Accrued interest payable		722,917			539,247
Loans from related party		28,469			9,769
Loans payable		2,322,900			1,845,500
Convertible notes payable, net of unamortized debt discount of $122,477 and $141,510, respectively		1,278,513			1,205,576
Convertible notes payable related party, net of unamortized discount of $640,995 and $895,079, respectively		1,984,982			1,495,948
Total current liabilities		7,275,387			5,626,625
Loans payable		—			436,000
Total liabilities		7,275,387			6,062,625
Stockholders' deficit
Common stock; $0.001 par value; 200,000,000 shares authorized; 119,573,969  and 115,701,969   shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively		119,574			115,702
Additional paid-in capital		22,364,366			22,053,555
Accumulated deficit		(29,408,625	)		(27,831,352	)
Total stockholders' deficit		(6,924,685	)		(5,662,095	)
Total liabilities and stockholders' deficit	$	350,702		$	400,530

See Accompanying Notes to Consolidated Financial Statements.

F-1

 SKINVISIBLE, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

	Three months ending						Nine months ending
	September 30, 2016			September 30, 2015			September 30, 2016			September 30, 2015
Revenues	$	16,807		$	30,377		$	83,258		$	158,428
Cost of revenues		32,583			9,859			46,595			56,047
Gross profit		(15,776	)		20,518			36,663			102,381
Operating expenses
Depreciation and amortization		14,378			14,631			43,331			43,377
Selling general and administrative		171,574			255,436			681,917			900,605
Total Operating Expenses		185,952			270,067			725,248			943,982
Loss from operations		(201,728	)		(249,549	)		(688,585	)		(841,601	)
Other income and (expense)
Other income		—			—			2			26
Interest expense		(282,262	)		(232,107	)		(891,282	)		(650,079	)
Gain (loss) on extinguishment of debt		—			400			2,592			1,840
Total other expense		(282,262	)		(231,707	)		(888,688	)		(648,213	)
Net loss	$	(483,990	)	$	(481,256	)	$	(1,577,273	)	$	(1,489,814	)
Basic loss per common share	$	(0.00	)	$	(0.00	)	$	(0.01	)	$	(0.01	)
Basic weighted average common shares outstanding		117,919,353			113,957,969			118,180,911			113,957,969

See Accompanying Notes to Consolidated Financial Statements

F-2

SKINVISIBLE, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

	Nine Months Ended
	September 30, 2016			September 30, 2015
Cash flows from operating activities:
Net loss	$	(1,577,273	)	$	(1,489,814	)
Adjustments to reconcile net loss to net
cash used in operating activities:
Depreciation and amortization		43,331			43,377
Stock-based compensation		133,445			8,800
Book overdraw		1,546			32,787
Amortization of debt discount		428,347			327,478
Gain on extinguishment of debt		(2,592	)		(1,840	)
Changes in operating assets and liabilities:
Increase in inventory		9,220			(6,596	)
Decrease in accounts receivable		(2,723	)		2,624
Increase in accounts payable and accrued liabilities		644,025			321,020
Increase in accrued interest		187,074			149,788
Net cash used in operating activities		(135,600	)		(612,376	)
Cash flows from investing activities:
Purchase of fixed and intangible assets		—			(5,726	)
Net cash used in investing activities		—			(5,726	)
Cash flows from financing activities:
Proceeds from sale of common stock		25,000			80,000
Proceeds from related party loans, net of payments		18,700			—
Payments on notes payable		(25,600	)		(89,500	)
Proceeds from notes payable		67,000			431,000
Proceeds from convertible notes payable		98,000			—
Payments on convertible notes payable		(47,500	)		—
Net cash provided by (used in) financing activities		135,600			421,500
Net change in cash		—			(196,602	)
Cash, beginning of period		—			196,602
Cash, end of period	$	—		$	—
Supplemental disclosure of cash flow information:
Cash paid for interest	$	17,589		$	211,564
Cash paid for tax	$	—		$	—
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Non-cash investing and financing activities:
Accrued expenses convereted to notes	$	232,950		$	118,126
Benefitial conversion feature	$	155,230		$	—
Common stock issued on extiguishment of debts	$	1,008		$	5,760

 See Accompanying Notes to Consolidated Financial Statements

F-3

SKINVISIBLE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

1. DESCRIPTION OF BUSINESS, HISTORY AND SUMMARY OF SIGNIFICANT POLICIES

Description of business – Skinvisible, Inc., (referred to as the “Company”) is focused on the development and manufacture and sales of innovative topical, transdermal and mucosal polymer-based delivery system technologies and formulations incorporating its patent-pending formula/process for combining hydrophilic and hydrophobic polymer emulsions. The technologies and formulations have broad industry applications within the pharmaceutical, over-the-counter, personal skincare and cosmetic arenas. Additionally, the Company’s non-dermatological formulations, offer solutions for a broad spectrum of markets women’s health, pain management, and others. The Company maintains executive and sales offices in Las Vegas, Nevada.

History – The Company was incorporated in Nevada on March 6, 1998, under the name of Microbial Solutions, Inc. The Company underwent a name change on February 26, 1999, when it changed its name to Skinvisible, Inc. The Company’s subsidiary’s name of Manloe Labs, Inc. was also changed to Skinvisible Pharmaceuticals, Inc.

On September 9, 2014, the Company formed Kinatri USA Inc., a wholly-owned subsidiary, to market a premium line of scientifically formulated skincare products powered by our patented Invisicare® technology. As part of its strategic focus on revenue generation and creating shareholder value, Kintari USA Inc. products will be sold via network marketing.

The Kintari product portfolio consists of anti-aging products to help fight the signs of aging. These products have been developed using proven anti-aging ingredients with scientific evidence of their effectiveness at reducing the look of fine lines and wrinkles resulting in youthful looking skin. These potent ingredients will be powered by patented Invisicare technology, providing consumers with unique, effective products which the Company believes cannot be duplicated. Additional products will be added to enhance this product line as the Company grows and expands.

Skinvisible, Inc., together with its subsidiaries, shall herein be collectively referred to as the “Company.”

Going concern – The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred cumulative net losses of $29,408,625 since its inception and requires capital for its contemplated operational and marketing activities to take place. The Company’s ability to raise additional capital through the future issuances of common stock is unknown. The obtainment of additional financing, the successful development of the Company’s contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. The ability to successfully resolve these factors raise substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.

Principles of consolidation – The consolidated financial statements include the accounts of the Company and its subsidiaries. All significant intercompany balances and transactions have been eliminated.

Use of estimates – The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Cash and cash equivalents

For purposes of the statement of cash flows, the Company considers all highly liquid investments and short-term debt instruments with original maturities of three months or less to be cash equivalents. There are $0 and $0 in cash and cash equivalents as of September 30, 2016 and December 31, 2015, respectively.

Fair Value of Financial Instruments

The carrying amounts reflected in the balance sheets for cash, accounts payable and accrued expenses approximate the respective fair values due to the short maturities of these items.

As required by the Fair Value Measurements and Disclosures Topic of the FASB ASC, fair value is measured based on a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: (Level 1) observable inputs such as quoted prices in active markets; (Level 2) inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and (Level 3) unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

F-4

SKINVISIBLE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The three levels of the fair value hierarchy are described below:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability;

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).

Revenue recognition

Product sales – Revenues from the sale of products (Invisicare® polymers) are recognized when title to the products are transferred to the customer and only when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive reasonably assured payments for products sold and delivered.

Royalty sales – The Company also recognizes royalty revenue from licensing its patented product formulations only when earned, when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments.

Distribution and license rights sales – The Company also recognizes revenue from distribution and license rights only when earned (and are amortized over a five year period), when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments.

Costs of Revenue – Cost of revenue includes raw materials, component parts, and shipping supplies. Shipping and handling costs is not a significant portion of the cost of revenue.

Accounts Receivable – Accounts receivable is comprised of uncollateralized customer obligations due under normal trade terms requiring payment within 30 days from the invoice date. The carrying amount of accounts receivable is reviewed periodically for collectability. If management determines that collection is unlikely, an allowance that reflects management’s best estimate of the amounts that will not be collected is recorded. Management reviews each accounts receivable balance that exceeds 30 days from the invoice date and, based on an assessment of creditworthiness, estimates the portion, if any, of the balance that will not be collected. As of September 30, 2016, the Company had not recorded a reserve for doubtful accounts. The Company has $1,135,000 in convertible notes payable which are secured by the accounts receivable of a license agreement the Company has with Women's Choice Pharmaceuticals, LLC on its proprietary prescription product, ProCort®.

Inventory – Substantially all inventory consists of finished goods and are valued based upon first-in first-out ("FIFO") cost, not in excess of market. The determination of whether the carrying amount of inventory requires a write-down is based on an evaluation of inventory.

Goodwill and intangible assets – The Company follows Financial Accounting Standard Board’s (FASB) Codification Topic 350-10 (“ASC 350-10”), “Intangibles – Goodwill and Other”. According to this statement, goodwill and intangible assets with indefinite lives are no longer subject to amortization, but rather an annual assessment of impairment by applying a fair-value based test. Fair value for goodwill is based on discounted cash flows, market multiples and/or appraised values as appropriate. Under ASC 350-10, the carrying value of assets are calculated at the lowest level for which there are identifiable cash flows.

Income taxes – The Company accounts for its income taxes in accordance with FASB Codification Topic ASC 740-10, “Income Taxes”, which requires recognition of deferred tax assets and liabilities for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

F-5

SKINVISIBLE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Stock-based compensation – The Company follows the guidelines in FASB Codification Topic ASC 718-10 “Compensation-Stock Compensation”, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and directors including employee stock options and employee stock purchases related to an Employee Stock Purchase Plan based on the estimated fair values.

Stock based compensation expense recognized under ASC 718-10 for the nine months ended September 30, 2016 and 2015 totaled $133,445 and $8,800, respectively.

Earnings (loss) per share – The Company reports earnings (loss) per share in accordance with FASB Codification Topic ASC 260-10 “Earnings Per Share”, Basic earnings (loss) per share is computed by dividing income (loss) available to common shareholders by the weighted average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted earnings (loss) per share has not been presented since the effect of the assumed exercise of options and warrants to purchase common shares (common stock equivalents) would have an anti-dilutive effect.

2. FIXED ASSETS

Fixed assets consist of the following as of September 30, 2016 and December 31, 2015:

		September 30, 2016		December 31, 2015
Machinery and equipment	$	48,163	$	48,163
Furniture and fixtures		113,635		113,635
Computers, equipment and software		39,722		39,722
Leasehold improvements		12,569		12,569
Lab equipment		113,461		113,461
Total		327,550		327,550
Less: accumulated depreciation		(326,786)		(325,855)
Fixed assets, net of accumulated depreciation	$	764	$	1,695

Depreciation expense for the nine months ended September 30, 2016 and 2015 was $931 and $1,185, respectively.

3. INVENTORY

Inventory consist of the following as of September 30, 2016 and December 31, 2015:

		September 30, 2016		December 31, 2015
Shipping and Packing materials	$	10,392	$	11,651
Marketing Supplies		17,322		19,346
Finished Goods		34,227		19,082
Raw Materials		19,811		40,893
Total	$	81,752	$	90,972

4.    INTANGIBLE AND OTHER ASSETS

Patents and trademarks are capitalized at their historical cost and are amortized over their estimated useful lives. As of September 30, 2016, patents and trademarks total $646,169, net of $386,851 of accumulated amortization. Amortization expense for the nine months ended September 30, 2016 and 2015 was $42,400 and $42,192, respectively.

License and distributor rights (“agreement”) were acquired by the Company in January 1999 and provide exclusive use distribution of polymers and polymer based products. The Company has a non-expiring term on the license and distribution rights. Accordingly, the Company annually assesses this license and distribution rights for impairment and has determined that no impairment write-down is considered necessary as of September 30, 2016.

F-6

SKINVISIBLE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

5. STOCK OPTIONS AND WARRANTS

The following is a summary of option activity during the nine months ended September 30, 2016.

	Number of Shares		Weighted Average Exercise Price
Balance, December 31, 2015		8.450.000	$	0.05
Options granted and assumed		4,150,000	$	0.02
Options expired		1,350,000	$	0.04
Options canceled		—		—
Options exercised		—		—
Balance, September 30, 2016		11,250,000	$	0.03

As of September 30, 2016, all stock options outstanding are exercisable.

On February 10, 2016, the Company granted stock options for 4,150,000 options to purchase shares of its common stock to its officers and directors. The options have a strike price of $0.02. The stock options were exercisable upon grant and have a life of 3 years. The stock options were valued at $99,167 using the Black-Scholes option pricing model.   The Company recorded an expense of $99,197 for the nine months ended September 30, 2016.

Stock warrants -

The following is a summary of warrants activity during the nine months ended September 30, 2016.

	Number of Shares		Weighted Average Exercise Price
Balance, December 31, 2015		2,969,750	$	0.06
Warrants granted and assumed		1,661,000		0.02
Warrants expired		1,344,750		0.06
Warrants canceled		—		—
Warrants exercised		—		—
Balance, September 30, 2016		3,286,000	$	0.04

All warrants outstanding as of September 30, 2016 are exercisable.

6. NOTES PAYABLE

On May 22, 2013, the Company approved a financing plan to offer accredited investors up to $1,000,000 in secured promissory notes. During the year ended December 31, 2013, the Company entered into twenty-four 9% notes payable to investors and received total proceeds of $1,000,000. The notes are due two years from the anniversary date of execution. The Notes are secured by the US Patent rights granted for the Company's Sunscreen Products: US patent number #8,128,913: "Sunscreen Composition with Enhanced UV-A Absorber Stability and Methods.” During nine months ending September 30, 2016 the Company made principal payments of $nil.

F-7

SKINVISIBLE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

On May 19, 2014, the Company approved a financing plan to offer accredited investors up to an additional $1,000,000 in secured promissory notes. For the period from May 19, 2014 to March 31, 2015 the Company entered into twenty-seven 9% notes payable to investors and received total proceeds of $1,000,000. The notes are due two years from the anniversary date of execution. The Notes are secured by the US Patent rights granted for the Company's Sunscreen Products: US patent number #8,128,913: "Sunscreen Composition with Enhanced UV-A Absorber Stability and Methods." As of September 30, 2016, $980,000 in notes have reached their initial maturity date. Note holders of $20,000 in debt executed agreements extending their notes for an additional 12 months upon the same terms. The extended note will fully mature on November 6, 2016.

During the period from April 1, 2015 and September 30, 2015, the Company entered into thirteen additional 9% notes payable to investors and received total proceeds of $326,000. The notes are due two years from the anniversary date of execution. The Notes are secured by the US Patent rights granted for the Company's Sunscreen Products: US patent number #8,128,913: "Sunscreen Composition with Enhanced UV-A Absorber Stability and Methods".

On January 27, 2016, the Company entered into a 12% unsecured note payable to an investor and received total proceeds of $33,000. The note was due on May 30, 2016.

On January 27, 2016, we entered into a promissory note pursuant to which we borrowed $24,000. Interest under the note is at 10% per annum, and the principal and all accrued but unpaid interest was due on February 15, 2016.

As of September 30, 2016, $2,322,900 of the Notes were due in less than 12 months and have been classified as current notes payable.

7.    RELATED PARTY TRANSACTIONS

During the nine months ended 2016, an officer advanced $18,700 to support the daily operations of the company. The advance is due on demand and bears no interest.

As of September 30, 2016, $28,469 remained due to related parties as repayment for advanced monies, all related other party notes have been extinguished or re-negotiated as convertible notes. See note 10.

F-8

SKINVISIBLE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

8. CONVERTIBLE NOTES PAYABLE

Convertible Notes Payable at consists of the following:	September 30,		December 31,
	2016		2015
$52,476 face value,10% unsecured note payable to an investor, note interest and principal are due on demand.  The note could be converted to option rights for the Company’s shares at ten cents per share ($0.10), these rights expired on January 12, 2010. The note is currently in default, but no penalties occur due to default.	$	28,476	$	28,476
Unamortized debt discount		-		-
Total, net of unamortized discount		28,476		28,476
$1,000,000 face value 9% secured notes payable to investors, due in 2015. At the investor’s option until the repayment date, the note and related interest may be converted to shares of the Company’s common stock a discount of 90% of the current share price after the first anniversary of the note. The notes are secured by the accounts receivable of a license agreement the Company has with Womens Choice Pharmaceuticals, LLC on its proprietary prescription product, ProCort®. The Company has determined the value associated with the beneficial conversion feature in connection with the notes and interest to be $111,110. The aggregate original issue discount feature has been accreted and charged to interest expenses as a financing expense. The original issue discount feature is valued under the intrinsic value method. The notes have reach maturity and are now in default, under the notes default provisions the entire balance is now due upon demand.		1,000,000		1,000,000
Original issue discount		111,110		111,110
Unamortized debt discount		-		-
Total, net of unamortized discount		1,111,110		1,111,110
On July 28, 2015, the Company entered into a convertible promissory note pursuant to which it borrowed $47,500. Interest under the convertible promissory note is 8% per annum, and the principal and all accrued but unpaid interest is due on April 30, 2016. The note is convertible at any time following 180 days after the issuance date at noteholders option into shares of our common stock at a variable conversion price of 58% of the lowest average three day market price of our common stock during the 10 trading days prior to the notice of conversion, subject to adjustment as described in the note. The holder’s ability to convert the note, however, is limited in that it will not be permitted to convert any portion of the note if the number of shares of our common stock beneficially owned by the holder and its affiliates, together with the number of shares of our common stock issuable upon any full or partial conversion, would exceed 9.99% of the Company’s outstanding shares of common stock. The Company has determined the value associated with the beneficial conversion feature in connection with the notes negotiated on July 28, 2015 to be $44,634. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $19,497 during the nine months ending September 30, 2016. The beneficial conversion feature is valued under the intrinsic value method During the nine months ending September 30, 2016, the Company paid $72,458 to the note holder to settle the note in full. The payment included interest and prepayment penalties of $24,958.		-		47,500
Unamortized debt discount		-		(19,497)
Total, net of unamortized discount		-		28,003
$135,000 face value 9% unsecured notes payable to investors, due October 26, 2017. At the investor’s option until the repayment date, the note and related interest may be converted to shares of the Company’s common stock a discount of 90% of the current share price after the first anniversary of the note. The notes are secured by the accounts receivable of a license agreement the Company has with Womens Choice Pharmaceuticals, LLC on its proprietary prescription product, ProCort®. The Company has determined the value associated with the beneficial conversion feature in connection with the notes and interest to be $117,535. The aggregate original issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $44,115 during the nine months ended September 30, 2016. The original issue discount feature is valued under the intrinsic value method.		135,000		135,000
Unamortized debt discount		(62,793)		(106,908)
Total, net of unamortized discount		72,207		28,092
On December 17, 2015, the Company entered into a convertible promissory note pursuant to which it borrowed $25,000. Interest under the convertible promissory note is 10% per annum, and the principal and all accrued but unpaid interest is due on May 17, 2016. The note is convertible into 1,250,000 shares of the Company’s common stock at a price of $0.02 per share and 625,000 warrants exercisable at $0.04 per share. The Company has determined the value associated with the beneficial conversion feature in connection with the notes negotiated on December 17, 2015 to be $16,648. The aggregate original issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $16,648 during the nine months ended September 30, 2016. The beneficial conversion feature is valued under the intrinsic value method The Note and all accrued interest was paid in full through the issuance of a new convertible note on August 31, 2016.		-		25,000
Unamortized debt discount		-		(15,104)
Total, net of unamortized discount		-		9,896
On February 1, 2016, the Company entered into a convertible promissory note pursuant to which it borrowed $25,000. Interest under the convertible promissory note is 10% per annum, and the principal and all accrued but unpaid interest is due on July 25, 2016. The note is convertible into 1,250,000 shares of the Company’s common stock at a price of $0.02 per share and 625,000 warrants exercisable at $0.02 per share. The Company has determined the value associated with the beneficial conversion feature in connection with the notes negotiated on February 1, 2016 to be $21,819. The aggregate original issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $21,819 during the nine months ended September 30, 2016. The beneficial conversion feature is valued under the intrinsic value method The Note and all accrued interest was paid in full through the issuance of a new convertible note on August 31, 2016.		-		-
Unamortized debt discount		-		-
Total, net of unamortized discount		-		-
On February 1, 2016, the Company entered into a convertible promissory note pursuant to which it borrowed $38,000. Interest under the convertible promissory note is 10% per annum, and the principal and all accrued but unpaid interest is due on February 15, 2017. The note is convertible into 1,900,000 shares of the Company’s common stock at a price of $0.02 per share and 950,000 warrants exercisable at $0.02 per share. The Company has determined the value associated with the beneficial conversion feature in connection with the notes negotiated on February 1, 2016 to be $33,164. The aggregate original issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $21,120 during the nine months ended September 30, 2016. The beneficial conversion feature is valued under the intrinsic value method		38,000		-
Unamortized debt discount		(12,044)		-
Total, net of unamortized discount		25,956		-
On February 17, 2016, the Company entered into a convertible promissory note pursuant to which it borrowed $20,000. Interest under the convertible promissory note is 9% per annum, and the principal and all accrued but unpaid interest is due on February 17, 2018. The note is convertible at any time following 90 days after the issuance date at noteholders option into shares of our common stock at a variable conversion price of 90% of the average five day market price of our common stock during the 5 trading days prior to the notice of conversion, subject to adjustment as described in the note. The holder’s ability to convert the note, however, is limited in that it will not be permitted to convert any portion of the note if the number of shares of our common stock beneficially owned by the holder and its affiliates, together with the number of shares of our common stock issuable upon any full or partial conversion, would exceed 4.99% of the Company’s outstanding shares of common stock. The Company has determined the value associated with the beneficial conversion feature in connection with the notes negotiated on February 27, 2016 to be $14,049. The aggregate original issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $4,349 during the nine months ended September 30, 2016. The beneficial conversion feature is valued under the intrinsic value method		20,000		-
Unamortized debt discount		(9,699)		-
Total, net of unamortized discount		10,301		-
On August 11, 2016, the Company entered into a convertible promissory note pursuant to which it borrowed $15,000. Interest under the convertible promissory note is 9% per annum, and the principal and all accrued but unpaid interest is due on August 11, 2018. The note is convertible into shares of our common stock at a variable conversion price of 90% of the average market price of our common stock during the 5 trading days prior to the notice of conversion, subject to adjustment as described in the note. The Company has determined the value associated with the beneficial conversion feature in connection with the notes negotiated on August 11, 2016 to be $14,728. The aggregate original issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $1,009 during the nine months ended September 30, 2016. The beneficial conversion feature is valued under the intrinsic value method		15,000		-
Unamortized debt discount		(13,719)		-
Total, net of unamortized discount		1,281		-
On August 31, 2016, the Company entered into a convertible promissory note pursuant to which it settled $50,000 in convertible notes and accrued interest of $3,404. Interest under the convertible promissory note is 10% per annum, and the principal and all accrued but unpaid interest is due on December 31, 2016. The note is convertible into 5,340,283 shares of the Company’s common stock at a price of $0.01 per share and 2,670,142 warrants exercisable at $0.02 per share. The Company has determined the value associated with the beneficial conversion feature in connection with the notes negotiated on August 31, 2016 to be $32,121. The aggregate original issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $7,899 during the nine months ended September 30, 2016. The beneficial conversion feature is valued under the intrinsic value method		53,404		-
Unamortized debt discount		(24,222)		-
Total, net of unamortized discount		29,182		-
	$	1,278,813	$	1,205,576

F-9

SKINVISIBLE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

9. CONVERTIBLE NOTES PAYABLE RELATED PARTY

Convertible Notes Payable Related Party at consists of the following:	September 30,		December 31,
	2016		2015
On December 31, 2011, the Company re-negotiated accrued salaries and interest for three employees. Under the terms of the agreements, the notes dated before December 31, 2010, and all salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.04 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.06 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes negotiated on December 31, 2011 to be $1,123,078. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $125,048 during the nine months ending September 30, 2016.  The beneficial conversion feature is valued under the intrinsic value method.  In the year ending December 2013, the Company  made $51,485 in cash payments to reduce the note balance.		1,071,593		1,071,593
Unamortized debt discount		(41,921)		(166,969)
On June 30, 2012, the Company re-negotiated accrued salaries and interest for three employees. Under the terms of the agreements, the notes dated before July 1, 2011, and all salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.04 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.06 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the  notes to be $209,809. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $31,212 during the nine months ending September 30, 2016.  The beneficial conversion feature is valued under the intrinsic value method.  On January 18, 2013, the Company  made a $3,990 cash payment to reduce the note balance.		321,032		321,032
Unamortized debt discount		(31,098)		(62,310)
On December 30 and 31, 2012, the Company re-negotiated accrued salaries and interest for three employees. Under the terms of the agreements, $182,083 of related party notes accrued interest and salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $182,083 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.03 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.04 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $182,083. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $27,323 during the nine months ending September 30, 2016.  The beneficial conversion feature is valued under the intrinsic value method.		182,083		182,083
Unamortized debt discount		(45,558)		(72,881)
On June 30, 2013, the Company re-negotiated accrued salaries and interest for two employees. Under the terms of the agreements, $106,153 of accrued interest and salaries were converted to promissory notes convertible into common stock with a warrant feature. The $106,153 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.03 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.04 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $70,768. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $10,619 during the nine months ending September 30, 2016.  The beneficial conversion feature is valued under the intrinsic value method.		106,152		106,152
Unamortized debt discount		(24,726)		(35,345)
On December 31, 2013, the Company re-negotiated accrued salaries and interest for three employees. Under the terms of the agreements, $142,501 of accrued interest and salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $142,501 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.03 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.04 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $94,909. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $14,241 during nine months ending September 30, 2016. The beneficial conversion feature is valued under the intrinsic value method.		142,501		142,501
Unamortized debt discount		(42,725)		(56,966)
On June 30, 2014, the Company re-negotiated accrued salaries and interest for three employees. Under the terms of the agreements, $118,126 of accrued salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $118,126 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.025 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.03 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $118,126. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $17,725 during the nine months ending September 30, 2016. The beneficial conversion feature is valued under the intrinsic value method.		118,126		118,126
Unamortized debt discount		(64,885)		(82,610)
On September 30, 2014, the Company re-negotiated accrued salaries and interest for two employees. Under the terms of the agreements, $40,558 of accrued salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $40,558 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.04 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.05 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $40,466. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $6,072 during nine months ending September 30, 2016. The beneficial conversion feature is valued under the intrinsic value method.		40,558		40,558
Unamortized debt discount		(24,266)		(30,338)
On December 31, 2014, the Company re-negotiated accrued salaries and interest for two employees. Under the terms of the agreements, $65,295 of accrued salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $65,295 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.04 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.05 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $57,439. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $8,619 during the nine months ending September 30, 2016. The beneficial conversion feature is valued under the intrinsic value method.		65,295		65,295
Unamortized debt discount		(37,338)		(45,957)
On December 31, 2015, the Company re-negotiated accrued salaries and interest for three employees and a director. Under the terms of the agreements, $343,687 of accrued salaries and director fees not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $343,687 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.02 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.02 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $341,703. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $51,247 during the nine months ending September 30, 2016. The beneficial conversion feature is valued under the intrinsic value method.		343,687		343,687
Unamortized debt discount		(290,456)		(341,703)
On March 30, 2016, the Company re-negotiated accrued directors fees of 3,600. Under the terms of the agreements, $3,600 of accrued director fees not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $3,600 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.02 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.02 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $864. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $110 during the nine months ending September 30, 2016. The beneficial conversion feature is valued under the intrinsic value method.		3,600		-
Unamortized debt discount		(764)		-
On April 30, 2016, the Company re-negotiated accrued salaries and interest for an employee. Under the terms of the agreements, $33,333 of accrued salaries were converted to promissory notes convertible into common stock with a warrant feature. The $33,333 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.02 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.02 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $8,401. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $620 during the nine months ending September 30, 2016. The beneficial conversion feature is valued under the intrinsic value method.		33,333		-
Unamortized debt discount		(7,781)		-
On June 30, 2016, the Company re-negotiated accrued salaries and interest for three employees. Under the terms of the agreements, $192,417 of accrued salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $192,417 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.02 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.02 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $28,365. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $1,429 during the nine months ending September 30, 2016.  The beneficial conversion feature is valued under the intrinsic value method.		192,417		-
Unamortized debt discount		(26,936)		-
On July 8, 2016, the Company re-negotiated accrued salaries and interest for one employee. Under the terms of the agreement, $2,000 of accrued salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $2,000 face value promissory notes are unsecured, due on December 31, 2021, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.01 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.02 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $1,012. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $42 during the nine months ending September 30, 2016. The beneficial conversion feature is valued under the intrinsic value method.		2000		-
Unamortized debt discount		(970)		-
On September 30, 2016, the Company re-negotiated accrued directors fees of 3,600. Under the terms of the agreements, $3,600 of accrued director fees not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $3,600 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.01 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.02 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $1,571. The aggregate beneficial conversion feature will be accreted and charged to interest expenses as a financing expense. The beneficial conversion feature is valued under the intrinsic value method.		3,600		-
Unamortized debt discount		(1,571)		-
	$	1,984,982	$	1,495,948

F-10

SKINVISIBLE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

10. STOCKHOLDERS’ DEFICIT

The Company is authorized to issue 200,000,000 shares of $0.001 par value common stock. The Company had 119,573,969 and 115,701,969 issued and outstanding shares of common stock as of September 30, 2016 and December 31, 2015, respectively.

On September 13, 2016, 2,500,000 shares of the Company’s common stock and 1,000,000 warrants exercisable at $0.02 were issued for a cash investment of $25,000.

On March 30, 2016, 72,000 shares of the Company’s common stock were issued to settle $3,600 of accrued expenses due to a director of the Company. A gain of $2.592 was recognized as a result of this settlement.

On January 27, 2016, the Company entered into a promissory note and pursuant to its terms the Company issued the holder 100,000 shares of its common stock valued at $0.02 per share. The shares were fair valued at $2,000 or $0.02 per   share.

On January 27, 2016, the Company entered into a promissory note and pursuant to its terms the Company issued the holder 200,000 shares of its common stock valued at $0.02 per share. The shares were fair valued at $4,980 or $0.0249 per share.

On February 1, 2016, the Company entered into a promissory note and pursuant to its terms the Company issued the holder 400,000 shares of its common stock valued at $0.02 per share. The shares were fair valued at $9,960 or $0.0249 per share.

On February 1, 2016, the Company entered into a promissory note and pursuant to its terms the Company issued the holder 250,000 shares of its common stock valued at $0.02 per share.   The shares were fair valued at $6,225 or $0.0249 per share.

On February 2, 2016, the Company issued of 400,000 shares of the Company’s common stock to five consultants for services related to the Company’s financing. The shares were fair valued at $9,960 or $0.0249 per share.

11. COMMITMENTS AND CONTINGENCIES

Lease obligations – The Company has operating leases for its offices. Future minimum lease payments under the operating leases for the facilities as of September 30, 2016, are as follows:

2016 8,576

2017 5,718

Rental expense, resulting from operating lease agreements, approximated $32,358 and $32,619 for the nine months ended September 30, 2016 and 2015, respectively.

On April 1, 2016, the Company licensed to Kintari Int. Inc. the following: the exclusive rights to its existing line of cosmeceutical products; the exclusive rights to any future cosmeceutical products developed by the Company; the right-of-first-refusal on its existing OTC products; and the right-of-first-refusal to any future OTC products developed by the Company. In exchange, the Company acquired 8,000,000 shares of Kintari Int. Inc.’s common stock. Kintari Int. Inc. is the Company’s wholly owned subsidiary. The material terms of the license with Skinvisible are as follows:

•  Kintari acquired the right to appoint sub-licensees provided that Skinvisible approves in advance.

• If Skinvisible desires to sell an OTC product, it must first notify Kintari. If Kintari desires to exercise the right-of-first-refusal on that OTC product, Kintari must launch the product within 6 months or lose it to Skinvisible.

• Kintari agreed to purchase the existing product inventory, raw ingredients, packaging materials plus all Kintari marketing materials for a total of $87,720.14. Kintari has not yet paid this amount and the parties are waiting for fundraising in connection with an offering to do so.

•  Skinvisible agreed to sell its polymers to Kintari and Kintari will manufacture the products using those polymers.

•  Kintari may use any of Skinvisible’s existing trademarks.

•  Kintari agreed to pay to Skinvisible an on-going royalty of 5% on revenue generated from the products.

•  Kintari agreed to pay to Skinvisible a minimum annual royalty equal to $50,000 for the first year after launch, $100,000 for the second year after launch and $150,000 for the third year after launch and each subsequent year for the term of the agreement.

•  Kintari agreed to pay to Skinvisible a royalty of 25% of any non-royalty payments received by Kintari from sub-licensees, including fees received in consideration for sublicensing the products.

•  The agreement may be terminated by, among other things, a mutual consent of the parties or a breach and failure to cure by one of the parties.

F-11

SKINVISIBLE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Kintari Int. Inc. commenced business in April 2016 in the U.S. and expects to begin operations in Canada in September 2016. Kintari Int. Inc. is the parent company to Kintari USA Inc. and Kintai Canana Inc. These companies will be used as operating entities to market and sell the products. Kintari Int. Inc. will need to raise capital of at least $2 million to assist with its development and payments to the Company. Kintari Int. Inc. plans to seek a TSX Venture Exchange listing upon completion of this financing.

12.    SUBSEQUENT EVENTS

On October 20, 2016, the Company re-negotiated accrued salaries and interest for an employee. Under the terms of the agreement, $18,000 of accrued salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The Company also refinanced $89,340 in notes issued in 2010 and 2011 through the issuance of a the new note. The $111,056 face value promissory note is unsecured, due on December 31, 2016, and bears an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.01 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.02 per share for three years after the conversion date.

On October 20, 2016, the Company re-negotiated $328,481 in unsecured notes payable for an employee. Under the terms of the original agreement, the promissory note was due on December 31, 2016, bears an interest rate of 10% and at the investor’s option until the repayment date, the note could be converted to shares of the Company’s common stock at a fixed price of $0.04 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.06 per share for three years after the conversion date. Under the modified terms that $328,481 face value note is now due on December 31, 2019, bears an interest rate of 10% and at the investor’s option until the repayment date, the note can be converted to shares of the Company’s common stock at a fixed price of $0.01 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.02 per share for three years after the conversion date.

On October 20, 2016, the Company re-negotiated $179,678 in unsecured notes payable for an employee. Under the terms of the original agreement, the promissory note was due on December 31, 2016, bears an interest rate of 10% and at the investor’s option until the repayment date, the note could be converted to shares of the Company’s common stock at a fixed price of $0.04 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.06 per share for three years after the conversion date. Under the modified terms that $179,678 face value note is now due on December 31, 2019, bears an interest rate of 10% and at the investor’s option until the repayment date, the note can be converted to shares of the Company’s common stock at a fixed price of $0.01 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.02 per share for three years after the conversion date.

On October 20, 2016, the Company re-negotiated $58,437 in unsecured notes payable for an employee. Under the terms of the original agreement, the promissory note was due on December 31, 2016, bears an interest rate of 10% and at the investor’s option until the repayment date, the note could be converted to shares of the Company’s common stock at a fixed price of $0.04 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.06 per share for three years after the conversion date. Under the modified terms that $58,437 face value note is now due on December 31, 2019, bears an interest rate of 10% and at the investor’s option until the repayment date, the note can be converted to shares of the Company’s common stock at a fixed price of $0.01 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.02 per share for three years after the conversion date.

On October 20, 2016, the Company re-negotiated $415,657 in unsecured notes payable for an employee. Under the terms of the original agreement, the promissory note was due on December 31, 2016, bears an interest rate of 10% and at the investor’s option until the repayment date, the note could be converted to shares of the Company’s common stock at a fixed price of $0.04 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.06 per share for three years after the conversion date. Under the modified terms that $415,657 face value note is now due on December 31, 2019, bears an interest rate of 10% and at the investor’s option until the repayment date, the note can be converted to shares of the Company’s common stock at a fixed price of $0.01 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.02 per share for three years after the conversion date.

On October 8, 2016, the Company entered into a 10% unsecured note payable to an employee and received total proceeds of $5,070. The note is due on December 31, 2016.

On October 11, 2016, the Company entered into a 10% unsecured note payable to an employee and received total proceeds of $5,000. The note is due on December 31, 2016.

On October 31, 2016, 3,333,350 shares of the Company’s common stock and 1,666,675 warrants exercisable at $0.025 were issued for a cash investment of $50,000.

F-12

Item 2.     Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.   These forward-looking statements generally are identified by the words “believes,” “project,” “expects,” “anticipates,” “estimates,” “intends,” “strategy,” “plan,” “may,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions.  We intend such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of complying with those safe-harbor provisions.  Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain.  Factors which could have a material adverse affect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.  We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.  Further information concerning our business, including additional factors that could materially affect our financial results, is included herein and in our other filings with the SEC.

Company Overview

We, through our wholly owned subsidiary Skinvisible Pharmaceuticals Inc., are a pharmaceutical research and development (“R&D”) company that has developed and patented an innovative polymer delivery system, Invisicare® and formulated over forty topical skin products, which we out-license globally. We were incorporated in 1998, and target an estimated $80 billion global skincare and dermatology market and a $30 billion global over-the-counter market as well as other healthcare / medical and consumer goods markets.

With the research and development complete on forty products and numerous patents issued (technology and product patents), we are ready to monetize our investment. Our business model will continue to be to out-license our patented prescription and over-the-counter (“OTC”) products featuring Invisicare to established manufacturers and marketers of brands internationally and to maximize profits from the products we have already out-licensed. We have also formed a commercial subsidiary, Kintari Int. Inc. with subsidiaries Kintari USA Inc. and Kintari Canada Inc., in order to take our cosmeceutical and select OTC products with Invisicare to market.

The opportunity for us to license our products continues to be a viable model as the need for pharmaceutical companies to access external R&D companies for new products due to their own down-sizing or elimination of internal R&D departments. The demand for our products is enhanced due to the granting of key US and international patents and the completed development of a number of unique products.

4

Our Plan for the Next Twelve Months

Our growth strategy is to:

1.       Generate revenue from direct sales of our cosmeceutical/OTC product line;

2.       Capitalize on the success of current licensees;

3.       Increase the value of our current pipeline; and

4.       Boost licensing revenues by securing additional licensees globally and develop a robust royalty revenue stream that will finance our future growth.

Direct Sales of our Cosmeceutical/OTC Product Line

Kintari USA Inc.:

On September 9, 2014, we formed Kintari USA Inc., a wholly-owned subsidiary of Kintari Int. Inc., which is a wholly-owned subsidiary of Skinvisible, Inc., to market a premium line of scientifically formulated skincare products powered by our patented Invisicare® technology. We launched Kintari USA Inc. on January 15, 2015. As part of our strategic focus on revenue generation and creating shareholder value, we plan to sell our products using a number of sales efforts, including our website, network marketing and distribution agreements. Our sales efforts are focused in the US, Canada and China.

Recent Sales Efforts

On September 15, 2016, we licensed the exclusive world rights to our topical and transdermal cannabis products formulated with Invisicare to CannaSkin, LLC, a cannabis product licensing company with international contacts in the medical marijuana industry.

CannaSkin has the exclusive license to manufacture, market and sub-license our new cannabis products. Their targets will initially include facilities in the 25 US jurisdictions currently approved for medical marijuana as well as Canada and Israel where there is a great demand for cannabis products supported by science.

Skinvisible has successfully formulated high-quality topical and transdermal cannabinoid products containing CBD and in the near future will add THC. CBD has proven to have many therapeutic effects and it does not produce the "high" associated with THC. Cannabinoids have been used for pain management and to treat many skin conditions, from acne, eczema, psoriasis, skin cancer, to anti-aging, due to their anti-oxidant and anti-inflammatory properties. Our Invisicare technology allows for the superior binding of these products to the skin, a controlled release of the cannabinoids both topically and transdermally, as well as providing patent protection. Cannabis is being touted as a groundbreaking health solution and Skinvisible plans to bring science-based, patent protected products into this emerging market.

On September 8, 2016, Kintari Int. Inc. signed an exclusive distribution agreement with EDFA Morgan Capital Co. Ltd. (“EMC”), located in Shenzhen, China, for Kintari® branded products for the territory of Greater China, which includes China, Hong Kong, Macau, Taiwan, Singapore, Malaysia and Thailand.

According to the agreement, EMC will sell Kintari products to Chinese consumers through a network of online shopping malls and other channels. Additionally, EMC has presented an opportunity to provide Skinvisible’s DermSafe® hand sanitizer to a chain of 3,000 hospitals in China through their electronic appointment app and

5

website. We believe there is significant value in making DermSafe accessible to 100 million Chinese patients through this service, as it currently supports over 3,000 hospitals, 46,000 doctors and was used to make over 257 million appointments. The potential market for DermSafe alone is vast as there are over 26,000 hospitals in China servicing a population of 1.6 billion people.

In addition to DermSafe, Skinvisible will supply its Kintari –branded portfolio of globally patented skincare products made with its Invisicare® delivery technology.

Product Line

The Kintari product portfolio consists of two anti-aging products to help fight the signs of aging, a broad spectrum sunscreen along with our latest products: Kintari’s Hand & Body lotion; and our topical and transdermal cannabis products. All products are made with our patented Invisicare technology.

Our anti-aging products have been developed using proven anti-aging ingredients with scientific evidence of their effectiveness at reducing the look of fine lines and wrinkles resulting in youthful looking skin. These potent ingredients will be powered by patented Invisicare technology, providing consumers with unique, effective products which we believe cannot be duplicated.

Our sunscreen is a broad spectrum SPF 30 known as Skinbrella®. We completed independent testing in early 2014 to validate our broad spectrum sunscreen claims according to the labeling guidelines of the FDA, which are designed to help reduce the incidents of skin cancer in the U.S. Our claims are as follows:

• Claim # 1 – Broad-Spectrum: According to the FDA, in order for a sunscreen to be labeled “broad spectrum” it must prove it protects against both UVA and UVB rays by having an SPF (Sun Protection Factor) of at least 15 and a critical wave length of at least 370 nm. Our sunscreen has surpassed both of these criteria, allowing our broad spectrum sunscreen label to also state “prevents sunburn, skin cancer and aging due to the sun.”

• Claim # 2 – Water-Resistant 80 Minutes: The FDA sunscreen water resistant claim requires that a sunscreen must have the same SPF after being in water or sweating for 40 or 80 minutes. Our testing was conducted at an independent laboratory specializing in sunscreen testing. The test involved human subjects that applied sunscreen to their arm, followed by the immersion of the arm into a Jacuzzi for 80 minutes (10 minutes in / 10 minutes out). Our sunscreen successfully completed this testing and is allowed to use “Water-resistant for 80 Minutes” on its sunscreen label, the longest length of time allowed by the FDA.

• Claim # 3 – Unique Patented Technology / Eight-Hour Photostability: As previously announced, we were granted a patent from the United States Patent and Trademark Office entitled “Sunscreen Composition with Enhanced UVA Absorber Stability and Methods”, which provides protection until November 2029. Skinvisible successfully formulated a unique Invisicare® delivery system specifically for stabilizing avobenzone; the key sunscreen used in the USA. Data submitted to the US patent office proved that our sunscreen provides a minimum of eight hours of photostability.

Our Hand & Body Lotion is formulated with five moisturizers including aloe, shea butter, glycerin, coconut oil and jojoba oil, and to help smooth your skin the powerful antioxidant Vitamin E. These ingredients restore and nourish your skin from head to toe.

Kintari Canada Inc.

Our hand sanitizer formulated with Invisicare® and chlorhexidine gluconate has been launched in Canada by subsidiary Kintari Canada Inc. where it has Health Canada approval. DermSafe is an alcohol free hand sanitizer that products against 99% of all germs. We are currently seeking licensees and/or distributors to begin the sale of DermSafe in South America and in the EU. We launched DermSafe in August, 2016 in Canada through our Kintari Canadian website for retail customers only.

6

In July, 2016, we announced that Kintari Canada made a donation of DermSafe to the Canadian Olympic Foundation offering protection for Canada’s athletes during the upcoming Olympic Games in Rio. Kintari Canada supplied the product to all Canadian Olympic athletes, trainers and support staff.

Capitalize On Current Licensees

We have: Avon Products globally and Women’s Choice Pharmaceuticals in the United States.

We continue to work diligently with our licensees to ensure they have a smooth manufacturing process, ongoing R&D support and marketing feedback.

Avon Products, Inc.

Product: We have a long-term contract with Avon globally for over ten years to provide Invisicare polymer for their long-lasting lipsticks.

Sales: Invisicare polymers are purchased directly from Skinvisible.

Women’s Choice Pharmaceuticals

Product: ProCort®, long lasting prescription hemorrhoid cream launched in the United States August 2011.

Sales and Royalties: Skinvisible receives a royalty based on net sales of ProCort. This past year Women's Choice Pharmaceuticals LLC partnered with Advanced Medical Enterprises, LLC to market ProCort® in Puerto Rico. With over thirty pharmaceutical sales reps calling on OBGYNs in the US, Women’s Choice has been successfully growing their sales of ProCort® and we look forward to increased growth in 2016. Women’s Choice is seeking to form other strategic alliances in order to increase its sales efforts by targeting new territories and targeting medical specialists which previously were not called upon

Additional Skinvisible Products

Sunless Tanning Products

We have developed a new sunless tanning mousse / foam which uses a unique foam with Invisicare®, developed specifically for its foaming properties. This adds to Skinvisible’s line of sunless tanning products which includes sunless tanning lotions (light, medium and dark), pre-sun moisturizer and after-sun moisturizer along with sunless tanning spray products for commercial use. The addition of a sunless tanning mousse enhances this line of products.

Sunscreen Products

We have developed 3 broad spectrum sunscreens, with SPF 15, 30 and 50 (the highest SPF allowed by the FDA). All are formulated with Avobenzone, the only UVA sun filter allowed under the US FDA monograph. This UVA/UVB sunscreen was granted a patent from the United States patent office in 2013. Avobenzone is known for breaking down in the sun after only two hours – thus the requirement to reapply every 2 hours. Skinvisible’s patent was granted based on Invisicare's® minimum 8 hour photo stability. For countries outside the United States, Skinvisible has additionally patented UVA/UVB sunscreens formulated with Tinosorb S.

Increasing The Value of Skinvisible’s Pipeline

We have a pipeline of over forty products which are available for licensing. Testing is conducted in-house generating proof of concept including release of the active ingredient as well as long term shelf life (stability). Additional studies conducted on specific products including skin sensitivity, toxicity and product efficacy are outsourced to FDA compliant laboratories. These studies are critical in attracting potential licensees. Our clinical strategy is to:

7

• Our clinical strategy is to find a partner for our prescription product portfolio. This would allow for a partner to seek FDA approval using the 505b2 pathway for one or more of our products.

• Launch of our DermSafe® hand sanitizer in Canada under Kintari. In 2013, we commissioned an independent laboratory to further analyze the long-term effectiveness of DermSafe® when put in contact with two bacteria; the “super bug” MRSA and E. coli, the “restaurant bug” since it is often transmitted by food and food handlers. The long-term effectiveness of two bacteria; Methicillin-resistant Staphylococcus aureus or MRSA (ATCC #33591) and Escherichia coli or E. coli (ATCC #43888") were tested up to four hours after application. The results showed that the individual arms of subjects which had DermSafe® applied and were even rinsed prior to each bacteria challenge, showed a 95.83% reduction at the 4 hour time point for MRSA and 99.38% for E. coli. In 2013, we obtained the registration rights for DermSafe® in Belgium. This designation allows for the sale and/ or registration of DermSafe in most EU countries. A strategy is being developed along with a larger global strategy to bring DermSafe to the EU and. Skinvisible has also commissioned further testing of DermSafe against the (Middle East Respiratory Syndrome Coronavirus (MERS-CoV); a SARS-like virus and the avian influenza A virus, H7N9.

• We continue to enhance our product developed for Netherton syndrome. Netherton syndrome is a disease caused by a genetic defect which causes the skin to continually exfoliate, never forming a skin bond. This leaves the patient highly susceptible to infection and dealing with a life-long condition that has no cure. Our product has shown excellent results in lab studies blocking the enzyme that breaks down the skin and we are seeking “Orphan Drug” designation in both the US (FDA) and Europe (EMA). We continue to investigate means to reformulate our product to better meet the demands of this very debilitating disease and are undergoing preliminary proof-of-concept investigations on Netherton syndrome.

• The advantages of obtaining Orphan Drug designation is that it provides various incentives including a reduction or elimination of registration and market authorization fees, protocol assistance, and seven years of market exclusivity for the product in the US and ten years in Europe. There can be no assurances that our project will be successful. Research and development for this project is currently on hold as we determine additional options for our formulation.

Secure Additional Licensees

We are in discussions and undergoing internal discussions with various pharmaceutical companies for licenses.

To facilitate further expansion, we are seeking an exclusive license with a proven US or global based Pharmaceutical Company for our existing Rx product formulations. The licensee would be expected to pay all costs in getting FDA approval. The licensee would pay Skinvisible for the license in milestone payments as Clinical Phases are proven.

Results of Operations for the Three and Nine Months Ended September 30, 2016 and 2015

Revenues

Our revenue from product sales, royalties on patent licenses and license fees for the three months ended September 30, 2016 was $16,807, a decrease from $30,377 for the same period ended September 30, 2015. Our revenue from product sales, royalties on patent licenses and license fees for the nine months ended September 30, 2016 was $83,258, a decrease from $158,428 for the same period ended September 30, 2015.

The decrease in revenue for the three and nine months ended September 30, 2016 was mainly due to a reduction in product sales. Our initial foray into network marketing was the main reasons for the decrease in sales. Several distributors were not successful in selling product and much of the product actually sold by these individuals was returned. Moreover, we ultimately terminated several of these distributorships, which resulted in repurchasing product. We are currently in the process of revamping our network marketing program, which we hope to establish for the last part of the year. We have also signed new distributors in the current quarter.

8

Cost of Revenues

Our cost of revenues for the three months ended September 30, 2016 increased to $32,583 from the prior year period when cost of revenues was $9,859. Our cost of revenues for the nine months ended September 30, 2016 decreased to $46,595 from the prior year period when cost of revenues was $56,047. Our cost of revenues increased for the three months ended September 30, 2016 over the prior year period as a result of spoilage of expired product. Our cost of revenues decreased for the nine months ended September 30, 2016 over the prior year periods as a result of decreased product sales. We expect our cost of revenues to increase as we continue to push sales from Kintari USA and Canada.

Gross Profit

Gross profit for the three months ended September 30, 2016 was ($15,776), or approximately -94% of sales. Gross profit for the three months ended September 30, 2015 was $20,518, or approximately 67% of sales. Gross profit for the nine months ended September 30, 2016 was $36,663, or approximately 44% of sales. Gross profit for the nine months ended September 30, 2015 was $102,381, or approximately 65% of sales. Our gross profit margin decreased in 2016 as compared with 2015, largely as a result of spoilage of product. If we do not experience increased sales going forward, we will have a similar trend in product spoilage. Although there can be no assurance, we are hopeful that our current licensing and marketing efforts will result in increased sales.

Operating Expenses

Operating expenses decreased to $185,952 for the three months ended September 30, 2016 from $270,067 for the same period ended September 30, 2015. Operating expenses decreased to $725,251 for the nine months ended September 30, 2016 from $943,982 for the same period ended September 30, 2015.

Our operating expenses for the nine months ended September 30, 2016 consisted mainly of accrued salaries and wages of $275,558, consulting fees of $212,501, depreciation and amortization expenses of $43,334, rent of $32,359, accounting and audit expenses of $27,046 and salaries and wages of $20,333. In comparison, our operating expenses for the nine months ended September 30, 2015 consisted mainly of accrued salaries and wages of $238,950, salaries and wages of $153,828, commissions of $115,483, consulting fees of $105,234, travel expenses of $64,875, depreciation and amortization expenses of $43,377, rent of $32,619, accounting and audit expenses of $28,092, license and permit fees of $20,232 and payroll tax expense of $19,320.

Other Expenses

We had other expenses of $282,262 for the three months ended September 30, 2016, compared with other expenses of $231,707 for the three months ended September 30, 2015. Other expenses was the result of interest expenses for the three months ended September 30, 2016 from $232,107 in interest expenses from prior period ended September 30, 2015.

We had other expenses of $888,688 for the nine months ended September 30, 2016, compared with other expenses of $648,213 for the nine months ended September 30, 2015. This was largely the result of $891,282 in interest expenses for the nine months ended September 30, 2016 from $650,079 in the prior period ended September 30, 2015.

We expect to continue to experience high interest payments in the future as a result of our outstanding liabilities. Moreover, as of the date of this report, there are a number of secured promissory notes with an aggregate principal amount of approximately $2,539,900 that have matured. In addition, we also have a number of unsecured promissory notes with an aggregate principal amount of $61,476 that have matured. If we are unable to generate sufficient revenues and/or additional financing to service this debt, there is a risk the lenders will call the notes, secure our assets, as to those applicable secured notes, and demand payment. If this happens, we could go out of business.

9

Net Loss

We recorded a net loss of $483,990 for the three months ended September 30, 2016, as compared with a net loss of $481,256 for the three months ended September 30, 2015. We recorded a net loss of $1,577,273 for the nine months ended September 30, 2016, as compared with a net loss of $1,489,814 for the nine months ended September 30, 2015.

Liquidity and Capital Resources

As of September 30, 2016, we had total current assets of $90,620 and total assets in the amount of $350,702. Our total current liabilities as of September 30, 2016 were $7,275,387. We had a working capital deficit of $7,184,767 as of September 30, 2016.

Operating activities used $135,600 in cash for the nine months ended September 30, 2016, as compared with $612,376 for the nine months ended September 30, 2015. Our net loss of $1,577,273 was the main component of our negative operating cash flow for the nine months ended September 30, 2016, offset mainly by an increase in accounts payable and accrued liabilities of $644,025, amortization of debt discount of $428,347, an increase in accrued interest of $187,074 and stock based compensation of $133,445. Our net loss of $1,489,814 was the main component of our negative operating cash flow for the nine months ended September 30, 2015, offset mainly by amortization of debt discount of $327,478, an increase in accounts payable and accrued liabilities of $321,020 and an increase of accrued interest of $149,788.

Cash flows provided by financing activities during the nine months ended September 30, 2016 amounted to $135,600, as compared with $421,500 for the nine months ended September 30, 2016. Our cash flows for the nine months ended September 30, 2016 consisted of $98,000 in proceeds from convertible notes payable, $67,000 in proceeds from notes payable, $25,000 in proceeds from the sale of our common stock and $18,700 in related party debt, offset by $47,500 in payments on convertible debt and $25,600 in payments on notes payable. Our cash flows for the nine months ended September 30, 2015 consisted of $431,000 in proceeds from notes payable and $80,000 in proceeds from the sale of common stock, offset by $89,500 in payments on notes payable.

On August 11, 2016, we entered into a convertible promissory note pursuant to which we borrowed $15,000. Interest under the convertible promissory note is 9% per annum, and the principal and all accrued but unpaid interest is due on August 11, 2018. The note is convertible into shares of our common stock at a variable conversion price of 90% of the average market price of our common stock during the 5 trading days prior to the notice of conversion, subject to adjustment as described in the note.

On August 31, 2016, we entered into a convertible promissory note pursuant to which we settled $50,000 in convertible notes and accrued interest of $3,404. Interest under the convertible promissory note is 10% per annum, and the principal and all accrued but unpaid interest is due on December 31, 2016. The note is convertible into 5,340,283 shares of our common stock at a price of $0.01 per share and warrants to purchase 2,670,142 shares of common stock exercisable at $0.02 per share.

On October 11, 2016, we entered into a 10% unsecured note payable to an employee and received total proceeds of $5,070. The note is due on December 31, 2016.

On October 31, 2016, 3,333,350 shares of our common stock and 1,666,675 warrants exercisable at $0.025 were issued for a cash investment of $50,000.

Based upon our current financial condition, we do not have sufficient cash to operate our business at the current level for the next twelve months. We intend to fund operations through increased sales and debt and/or equity financing arrangements, which may be insufficient to fund expenditures or other cash requirements. We plan to seek additional financing in a private equity offering to secure funding for operations. There can be no assurance that we will be successful in raising additional funding. If we are not able to secure additional funding, the implementation of our business plan will be impaired. There can be no assurance that such additional financing will be available to us on acceptable terms or at all.

10

Off Balance Sheet Arrangements

As of September 30, 2016, there were no off balance sheet arrangements.

Critical Accounting Policies

In December 2001, the SEC requested that all registrants list their most “critical accounting polices” in the Management Discussion and Analysis. The SEC indicated that a “critical accounting policy” is one which is both important to the portrayal of a company’s financial condition and results, and requires management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain.

Going concern – The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. We have incurred cumulative net losses of $29,408,625 since our inception and require capital for our contemplated operational and marketing activities to take place. Our ability to raise additional capital through the future issuances of common stock is unknown. The obtainment of additional financing, the successful development of our contemplated plan of operations, and our transition, ultimately, to the attainment of profitable operations are necessary for us to continue operations. The ability to successfully resolve these factors raise substantial doubt about our ability to continue as a going concern. These consolidated financial statements do not include any adjustments that may result from the outcome of these aforementioned uncertainties.

Product sales – Revenues from the sale of products (Invisicare® polymers) are recognized when title to the products are transferred to the customer and only when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive reasonably assured payments for products sold and delivered.

Royalty sales – We also recognize royalty revenue from licensing our patented product formulations only when earned, with no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments.

Distribution and license rights sales – We also recognize revenue from distribution and license rights only when earned (and are amortized over a five year period), with no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments.

Costs of Revenue – Cost of revenue includes raw materials, component parts, and shipping supplies. Shipping and handling costs is not a significant portion of the cost of revenue.

Accounts Receivable – Accounts receivable is comprised of uncollateralized customer obligations due under normal trade terms requiring payment within 30 days from the invoice date. The carrying amount of accounts receivable is reviewed periodically for collectability. If management determines that collection is unlikely, an allowance that reflects management’s best estimate of the amounts that will not be collected is recorded. Management reviews each accounts receivable balance that exceeds 30 days from the invoice date and, based on an assessment of creditworthiness, estimates the portion, if any, of the balance that will not be collected. As of September 30, 2016, the Company had not recorded a reserve for doubtful accounts. The Company has $1,000,000 in convertible notes payable which are secured by the accounts receivable of a license agreement the Company has with Women's Choice Pharmaceuticals, LLC on its proprietary prescription product, ProCort®.

Recently Issued Accounting Pronouncements

We do not expect the adoption of recently issued accounting pronouncements to have a significant impact on our results of operations, financial position or cash flow.

Item 3.     Quantitative and Qualitative Disclosures About Market Risk

A smaller reporting company is not required to provide the information required by this Item.

Item 4.     Controls and Procedures

11

Disclosure Controls and Procedures

We carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of September 30, 2016. This evaluation was carried out under the supervision and with the participation of our Chief Executive Officer and our Chief Financial Officer. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of September 30, 2016, our disclosure controls and procedures were not effective due to the presence of material weaknesses in internal control over financial reporting.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company’s annual or interim financial statements will not be prevented or detected on a timely basis. Management has identified the following material weaknesses which have caused management to conclude that, as of September 30, 2016, our disclosure controls and procedures were not effective: (i) inadequate segregation of duties and effective risk assessment; and (ii) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of both US GAAP and SEC guidelines.

Remediation Plan to Address the Material Weaknesses in Internal Control over Financial Reporting

Our company plans to take steps to enhance and improve the design of our internal controls over financial reporting. During the period covered by this quarterly report on Form 10-Q, we have not been able to remediate the material weaknesses identified above. To remediate such weaknesses, we plan to implement the following changes during our fiscal year ending December 31, 2016: (i) appoint additional qualified personnel to address inadequate segregation of duties and ineffective risk management; and (ii) adopt sufficient written policies and procedures for accounting and financial reporting. The remediation efforts set out are largely dependent upon our securing additional financing to cover the costs of implementing the changes required. If we are unsuccessful in securing such funds, remediation efforts may be adversely affected in a material manner.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the three months ended September 30, 2016 that have materially affected, or are reasonable likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1.     Legal Proceedings

We are not a party to any pending legal proceeding. We are not aware of any pending legal proceeding to which any of our officers, directors, or any beneficial holders of 5% or more of our voting securities are adverse to us or have a material interest adverse to us.

Item 2.     Unregistered Sales of Equity Securities and Use of Proceeds

The information set forth below relates to our issuances of securities without registration under the Securities Act of 1933 during the reporting period which were not previously included in a an Annual Report on Form 10-K, Quarterly Report on Form 10-Q or Current Report on Form 8-K.

On July 8, 2016, we re-negotiated accrued salaries and interest for an employee. Under the terms of the agreement, $2,000 of accrued salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $2,000 face value promissory notes are unsecured, due on December 31, 2021, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of our common stock at a fixed price of $0.01 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.02 per share for three years after the conversion date.

12

On August 11, 2016, we entered into a convertible promissory note pursuant to which we borrowed $15,000. The note is convertible into shares of our common stock at a variable conversion price of 90% of the average market price of our common stock during the 5 trading days prior to the notice of conversion, subject to adjustment as described in the note.

On August 31, 2016, we entered into a convertible promissory note pursuant to which we settled $50,000 in convertible notes and accrued interest of $3,404. The note is convertible into 5,340,283 shares of our common stock at a price of $0.01 per share and warrants to purchase 2,670,142 shares of common stock exercisable at $0.02 per share.

On September 13, 2016, 2,500,000 shares of our common stock and warrants to purchase 1,000,000 shares of common stock exercisable at $0.02 were issued for a cash investment of $25,000.

On September 30, 2016, we re-negotiated accrued directors’ fees of 3,600. Under the terms of the agreements, $3,600 of accrued director fees not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $3,600 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of our common stock at a fixed price of $0.02 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.02 per share for three years after the conversion date. We have determined the value associated with the beneficial conversion feature in connection with the notes to be $1,571.

On October 20, 2016, we re-negotiated accrued salaries and interest and refinanced unsecured promissory notes for employees of the company. Under the terms of the agreement, $1,089,593 of accrued salaries and interest and unsecured promissory notes were modified into promissory notes convertible into common stock with a warrant feature. At the investor’s option until the repayment date, the note may be converted to shares of our common stock at a fixed price of $0.01 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.02 per share for three years after the conversion date.

On October 31, 2016, 3,333,350 shares of our common stock and 1,666,675 warrants exercisable at $0.025 were issued for a cash investment of $50,000.

These securities were issued pursuant to Section 4(2) of the Securities Act and/or Rule 506 promulgated thereunder. The holders represented their intention to acquire the securities for investment only and not with a view towards distribution. The investors were given adequate information about us to make an informed investment decision. We did not engage in any general solicitation or advertising. We directed our transfer agent to issue the stock certificates with the appropriate restrictive legend affixed to the restricted stock.

Item 3.     Defaults upon Senior Securities

None

Item 4.     Mine Safety Disclosures

Not applicable.

Item 5.     Other Information

None

13

Item 6.      Exhibits

Exhibit Number	Description of Exhibit
31.1	Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101**	The following materials from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2016 formatted in Extensible Business Reporting Language (XBRL).
**Provided herewith

14

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Skinvisible, Inc.
Date:	November 17, 2016
	By: /s/ Terry Howlett Terry Howlett Title:   Chief Executive Officer, Chief Financial Officer and Director

15

EX-31.1

CERTIFICATIONS

I, Terry Howlett, certify that;

1. I have reviewed this quarterly report on Form 10-Q for the quarter ended September 30, 2016 of Skinvisible, Inc. (the “registrant”);

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 17, 2016

/s/ Terry Howlett

By: Terry Howlett

Title: Chief Executive Officer

EX-31.2

CERTIFICATIONS

I, Terry Howlett, certify that;

1. I have reviewed this quarterly report on Form 10-Q for the quarter ended September 30, 2016 of Skinvisible, Inc. (the “registrant”);

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 17, 2016

/s/ Terry Howlett

By: Terry Howlett

Title: Chief Financial Officer

EX-32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND

CHIEF FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly Report of Skinvisible, Inc. (the “Company”) on Form 10-Q for the quarter ended September 30, 2016 filed with the Securities and Exchange Commission (the “Report”), I, Terry Howlett, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1.The Report fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and

2.The information contained in the Report fairly presents, in all material respects, the consolidated financial condition of the Company as of the dates presented and the consolidated result of operations of the Company for the periods presented.

By:	/s/ Terry Howlett
Name:	Terry Howlett
Title:	Principal Executive Officer, Principal Financial Officer and Director
Date:	November 17, 2016

This certification has been furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

XML

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2016	Nov. 02, 2016
Document And Entity Information
Entity Registrant Name	Skinvisible Inc
Entity Central Index Key	0001085277
Document Type	10-Q
Document Period End Date	Sep. 30, 2016
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	No
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		123,835,319
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2016

XML

Balance Sheets - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Current assets
Cash
Accounts receivable	7,723	5,000
Inventory	81,752	90,972
Due from related party	1,145	1,145
Prepaid expense and other current assets
Total current assets	90,620	97,117
Fixed assets, net of accumulated depreciation of $326,786 and $325,855, respectively	764	1,695
Intangible and other assets:
Patents and trademarks, net of accumulated amortization of $386,851 and $344,451, respectively	259,318	301,718
Total assets	350,702	400,530
Current liabilities
Accounts payable and accrued liabilities	934,720	529,245
Bank overdraw	2,886	1,340
Accrued interest payable	722,917	539,247
Loans from related party	28,469	9,769
Loans payable	2,322,900	1,845,500
Convertible notes payable, net of unamortized debt discount of $122,477 and $141,510, respectively	1,278,813	1,205,576
Convertible notes payable related party, net of unamortized discount of $640,995 and $895,079, respectively	1,984,982	1,495,948
Total current liabilities	7,275,387	5,626,625
Loans payable		436,000
Total liabilities	7,275,387	6,062,625
Stockholders' deficit
Common stock; $0.001 par value; 200,000,000 shares authorized; 119,573,969 and 115,701,969 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively	119,574	115,702
Additional paid-in capital	22,364,366	22,053,555
Accumulated deficit	(29,408,625)	(27,831,352)
Total stockholders' deficit	(6,924,685)	(5,662,095)
Total liabilities and stockholders' deficit	$ 350,702	$ 400,530

XML

Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Common Stock, Par Value	$ 0.001	$ 0.001
Common Stock, Shares Authorized	200,000,000	200,000,000
Common Stock, Issued	119,573,969	115,701,969
Accumulated Depreciation	$ 326,786	$ 325,855
Convertible Notes Payable, net of unamortized debt discount	122,477	141,510
Convertible Notes Payable, related party, net of unamortized discount	640,995	895,079
Accumulated Amortization	$ 386,851	$ 344,451

XML

Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Income Statement [Abstract]
Revenues	$ 16,807	$ 30,377	$ 83,258	$ 158,428
Cost of revenues	32,583	9,859	46,595	56,047
Gross profit	(15,776)	20,518	36,663	102,381
Operating expenses
Depreciation and amortization	14,378	14,631	43,331	43,377
Selling general and administrative	171,574	255,436	681,917	900,605
Total Operating Expenses	185,952	270,067	725,248	943,982
Loss from operations	(201,728)	(249,549)	(688,585)	(841,601)
Other income and (expense)
Other income			(2)	(26)
Interest expense	282,262	232,107	891,282	650,079
Gain (loss) on extinguishment of debt			2,592	1,840
Total other expense	282,262	231,707	888,688	648,213
Net loss	$ (483,990)	$ (481,256)	$ (1,577,273)	$ (1,489,814)
Basic loss per common share	$ (0.00)	$ (0.00)	$ (0.01)	$ (0.01)
Basic weighted average common shares outstanding	117,919,353	113,957,969	118,180,911	113,957,969

XML

Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash flows from operating activities:
Net loss	$ (1,577,273)	$ (1,489,814)
Depreciation and amortization	43,331	43,377
Stock-based compensation	133,445	8,800
Book overdraw	1,546	32,787
Amortization of debt discount	428,347	327,478
Gain on extinguishment of debt	(2,592)	(1,840)
Changes in operating assets and liabilities:
Increase in inventory	9,220	(6,596)
Decrease in accounts receivable	(2,723)	2,624
Increase in accounts payable and accrued liabilities	644,025	321,020
Increase in accrued interest	187,074	149,788
Net cash used in operating activities	(135,600)	(612,376)
Cash flows from investing activities:
Purchase of fixed and intangible assets		(5,726)
Net cash used in investing activities		(5,726)
Cash flows from financing activities:
Proceeds from sale of common stock	25,000	80,000
Proceeds from related party loans, net of payments	18,700
Payments on notes payable	(25,600)	(89,500)
Proceeds from notes payable	67,000	431,000
Proceeds from convertible notes payable	98,000
Payments on convertible notes payable	47,500
Net cash provided by (used in) financing activities	135,600	421,500
Net change in cash		(196,602)
Cash, beginning of period
Cash, end of period
Supplemental disclosure of cash flow information:
Cash paid for interest	17,589	211,564
Cash paid for tax
Non-cash investing and financing activities:
Accrued expenses convereted to notes	232,950	118,126
Benefitial conversion feature	155,230
Common stock issued on extiguishment of debts	$ 1,008	$ 5,760

XML

DESCRIPTION OF BUSINESS, HISTORY AND SUMMARY OF SIGNIFICANT POLICIES

9 Months Ended

Sep. 30, 2016

Accounting Policies [Abstract]

DESCRIPTION OF BUSINESS, HISTORY AND SUMMARY OF SIGNIFICANT POLICIES

1. DESCRIPTION OF BUSINESS, HISTORY AND SUMMARY OF SIGNIFICANT POLICIES

Description of business – Skinvisible, Inc., (referred to as the “Company”) is focused on the development and manufacture and sales of innovative topical, transdermal and mucosal polymer-based delivery system technologies and formulations incorporating its patent-pending formula/process for combining hydrophilic and hydrophobic polymer emulsions. The technologies and formulations have broad industry applications within the pharmaceutical, over-the-counter, personal skincare and cosmetic arenas. Additionally, the Company’s non-dermatological formulations, offer solutions for a broad spectrum of markets women’s health, pain management, and others. The Company maintains executive and sales offices in Las Vegas, Nevada.

History – The Company was incorporated in Nevada on March 6, 1998, under the name of Microbial Solutions, Inc. The Company underwent a name change on February 26, 1999, when it changed its name to Skinvisible, Inc. The Company’s subsidiary’s name of Manloe Labs, Inc. was also changed to Skinvisible Pharmaceuticals, Inc.

On September 9, 2014, the Company formed Kinatri USA Inc., a wholly-owned subsidiary, to market a premium line of scientifically formulated skincare products powered by our patented Invisicare® technology. As part of its strategic focus on revenue generation and creating shareholder value, Kintari USA Inc. products will be sold via network marketing.

The Kintari product portfolio consists of anti-aging products to help fight the signs of aging. These products have been developed using proven anti-aging ingredients with scientific evidence of their effectiveness at reducing the look of fine lines and wrinkles resulting in youthful looking skin. These potent ingredients will be powered by patented Invisicare technology, providing consumers with unique, effective products which the Company believes cannot be duplicated. Additional products will be added to enhance this product line as the Company grows and expands.

Skinvisible, Inc., together with its subsidiaries, shall herein be collectively referred to as the “Company.”

Going concern – The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred cumulative net losses of $29,408,625 since its inception and requires capital for its contemplated operational and marketing activities to take place. The Company’s ability to raise additional capital through the future issuances of common stock is unknown. The obtainment of additional financing, the successful development of the Company’s contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. The ability to successfully resolve these factors raise substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.

Principles of consolidation – The consolidated financial statements include the accounts of the Company and its subsidiaries. All significant intercompany balances and transactions have been eliminated.

Use of estimates – The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Cash and cash equivalents

For purposes of the statement of cash flows, the Company considers all highly liquid investments and short-term debt instruments with original maturities of three months or less to be cash equivalents. There are $0 and $0 in cash and cash equivalents as of September 30, 2016 and December 31, 2015, respectively.

Fair Value of Financial Instruments

The carrying amounts reflected in the balance sheets for cash, accounts payable and accrued expenses approximate the respective fair values due to the short maturities of these items.

As required by the Fair Value Measurements and Disclosures Topic of the FASB ASC, fair value is measured based on a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: (Level 1) observable inputs such as quoted prices in active markets; (Level 2) inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and (Level 3) unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

The three levels of the fair value hierarchy are described below:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability;

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).

Revenue recognition

Product sales – Revenues from the sale of products (Invisicare® polymers) are recognized when title to the products are transferred to the customer and only when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive reasonably assured payments for products sold and delivered.

Royalty sales – The Company also recognizes royalty revenue from licensing its patented product formulations only when earned, when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments.

Distribution and license rights sales – The Company also recognizes revenue from distribution and license rights only when earned (and are amortized over a five year period), when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments.

Costs of Revenue – Cost of revenue includes raw materials, component parts, and shipping supplies. Shipping and handling costs is not a significant portion of the cost of revenue.

Accounts Receivable – Accounts receivable is comprised of uncollateralized customer obligations due under normal trade terms requiring payment within 30 days from the invoice date. The carrying amount of accounts receivable is reviewed periodically for collectability. If management determines that collection is unlikely, an allowance that reflects management’s best estimate of the amounts that will not be collected is recorded. Management reviews each accounts receivable balance that exceeds 30 days from the invoice date and, based on an assessment of creditworthiness, estimates the portion, if any, of the balance that will not be collected. As of September 30, 2016, the Company had not recorded a reserve for doubtful accounts. The Company has $1,135,000 in convertible notes payable which are secured by the accounts receivable of a license agreement the Company has with Women's Choice Pharmaceuticals, LLC on its proprietary prescription product, ProCort®.

Inventory – Substantially all inventory consists of finished goods and are valued based upon first-in first-out ("FIFO") cost, not in excess of market. The determination of whether the carrying amount of inventory requires a write-down is based on an evaluation of inventory.

Goodwill and intangible assets – The Company follows Financial Accounting Standard Board’s (FASB) Codification Topic 350-10 (“ASC 350-10”), “Intangibles – Goodwill and Other”. According to this statement, goodwill and intangible assets with indefinite lives are no longer subject to amortization, but rather an annual assessment of impairment by applying a fair-value based test. Fair value for goodwill is based on discounted cash flows, market multiples and/or appraised values as appropriate. Under ASC 350-10, the carrying value of assets are calculated at the lowest level for which there are identifiable cash flows.

Income taxes – The Company accounts for its income taxes in accordance with FASB Codification Topic ASC 740-10, “Income Taxes”, which requires recognition of deferred tax assets and liabilities for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

Stock-based compensation – The Company follows the guidelines in FASB Codification Topic ASC 718-10 “Compensation-Stock Compensation”, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and directors including employee stock options and employee stock purchases related to an Employee Stock Purchase Plan based on the estimated fair values.

Stock based compensation expense recognized under ASC 718-10 for the nine months ended September 30, 2016 and 2015 totaled $133,445 and $8,800, respectively.

Earnings (loss) per share – The Company reports earnings (loss) per share in accordance with FASB Codification Topic ASC 260-10 “Earnings Per Share”, Basic earnings (loss) per share is computed by dividing income (loss) available to common shareholders by the weighted average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted earnings (loss) per share has not been presented since the effect of the assumed exercise of options and warrants to purchase common shares (common stock equivalents) would have an anti-dilutive effect.

XML

FIXED ASSETS

9 Months Ended

Sep. 30, 2016

Property, Plant and Equipment [Abstract]

FIXED ASSETS

2. FIXED ASSETS

Fixed assets consist of the following as of September 30, 2016 and December 31, 2015:

		September 30, 2016		December 31, 2015
Machinery and equipment	$	48,163	$	48,163
Furniture and fixtures		113,635		113,635
Computers, equipment and software		39,722		39,722
Leasehold improvements		12,569		12,569
Lab equipment		113,461		113,461
Total		327,550		327,550
Less: accumulated depreciation		(326,786)		(325,855)
Fixed assets, net of accumulated depreciation	$	764	$	1,695

Depreciation expense for the nine months ended September 30, 2016 and 2015 was $931 and $1,185, respectively.

XML

INVENTORY

9 Months Ended

Sep. 30, 2016

Inventory Disclosure [Abstract]

INVENTORY

3. INVENTORY

Inventory consist of the following as of September 30, 2016 and December 31, 2015:

		September 30, 2016		December 31, 2015
Shipping and Packing materials	$	10,392	$	11,651
Marketing Supplies		17,322		19,346
Finished Goods		34,227		19,082
Raw Materials		19,811		40,893
Total	$	81,752	$	90,972

XML

INTANGIBLE AND OTHER ASSETS

9 Months Ended

Sep. 30, 2016

Notes to Financial Statements

INTANGIBLE AND OTHER ASSETS

4.    INTANGIBLE AND OTHER ASSETS

Patents and trademarks are capitalized at their historical cost and are amortized over their estimated useful lives. As of September 30, 2016, patents and trademarks total $646,169, net of $386,851 of accumulated amortization. Amortization expense for the nine months ended September 30, 2016 and 2015 was $42,400 and $42,192, respectively.

License and distributor rights (“agreement”) were acquired by the Company in January 1999 and provide exclusive use distribution of polymers and polymer based products. The Company has a non-expiring term on the license and distribution rights. Accordingly, the Company annually assesses this license and distribution rights for impairment and has determined that no impairment write-down is considered necessary as of September 30, 2016.

XML

STOCK OPTIONS AND WARRANTS

9 Months Ended

Sep. 30, 2016

Temporary Equity Disclosure [Abstract]

STOCK OPTIONS AND WARRANTS

5. STOCK OPTIONS AND WARRANTS

The following is a summary of option activity during the nine months ended September 30, 2016.

	Number of Shares		Weighted Average Exercise Price
Balance, December 31, 2015		8.450.000	$	0.05
Options granted and assumed		4,150,000	$	0.02
Options expired		1,350,000	$	0.04
Options canceled		—		—
Options exercised		—		—
Balance, September 30, 2016		11,250,000	$	0.03

As of September 30, 2016, all stock options outstanding are exercisable.

On February 10, 2016, the Company granted stock options for 4,150,000 options to purchase shares of its common stock to its officers and directors. The options have a strike price of $0.02. The stock options were exercisable upon grant and have a life of 3 years. The stock options were valued at $99,167 using the Black-Scholes option pricing model.   The Company recorded an expense of $99,197 for the nine months ended September 30, 2016.

Stock warrants -

The following is a summary of warrants activity during the nine months ended September 30, 2016.

	Number of Shares		Weighted Average Exercise Price
Balance, December 31, 2015		2,969,750	$	0.06
Warrants granted and assumed		1,661,000		0.02
Warrants expired		1,344,750		0.06
Warrants canceled		—		—
Warrants exercised		—		—
Balance, September 30, 2016		3,286,000	$	0.04

All warrants outstanding as of September 30, 2016 are exercisable.

XML

NOTES PAYABLE

9 Months Ended

Sep. 30, 2016

Notes to Financial Statements

NOTES PAYABLE

6. NOTES PAYABLE

On May 22, 2013, the Company approved a financing plan to offer accredited investors up to $1,000,000 in secured promissory notes. During the year ended December 31, 2013, the Company entered into twenty-four 9% notes payable to investors and received total proceeds of $1,000,000. The notes are due two years from the anniversary date of execution. The Notes are secured by the US Patent rights granted for the Company's Sunscreen Products: US patent number #8,128,913: "Sunscreen Composition with Enhanced UV-A Absorber Stability and Methods.” During nine months ending September 30, 2016 the Company made principal payments of $nil.

On May 19, 2014, the Company approved a financing plan to offer accredited investors up to an additional $1,000,000 in secured promissory notes. For the period from May 19, 2014 to March 31, 2015 the Company entered into twenty-seven 9% notes payable to investors and received total proceeds of $1,000,000. The notes are due two years from the anniversary date of execution. The Notes are secured by the US Patent rights granted for the Company's Sunscreen Products: US patent number #8,128,913: "Sunscreen Composition with Enhanced UV-A Absorber Stability and Methods." As of September 30, 2016, $980,000 in notes have reached their initial maturity date. Note holders of $20,000 in debt executed agreements extending their notes for an additional 12 months upon the same terms. The extended note will fully mature on November 6, 2016.

During the period from April 1, 2015 and September 30, 2015, the Company entered into thirteen additional 9% notes payable to investors and received total proceeds of $326,000. The notes are due two years from the anniversary date of execution. The Notes are secured by the US Patent rights granted for the Company's Sunscreen Products: US patent number #8,128,913: "Sunscreen Composition with Enhanced UV-A Absorber Stability and Methods".

On January 27, 2016, the Company entered into a 12% unsecured note payable to an investor and received total proceeds of $33,000. The note was due on May 30, 2016.

On January 27, 2016, we entered into a promissory note pursuant to which we borrowed $24,000. Interest under the note is at 10% per annum, and the principal and all accrued but unpaid interest was due on February 15, 2016.

As of September 30, 2016, $2,322,900 of the Notes were due in less than 12 months and have been classified as current notes payable.

XML

RELATED PARTY TRANSACTIONS

9 Months Ended

Sep. 30, 2016

Related Party Transactions [Abstract]

RELATED PARTY TRANSACTIONS

7.    RELATED PARTY TRANSACTIONS

During the nine months ended 2016, an officer advanced $18,700 to support the daily operations of the company. The advance is due on demand and bears no interest.

As of September 30, 2016, $28,469 remained due to related parties as repayment for advanced monies, all related other party notes have been extinguished or re-negotiated as convertible notes. See note 10.

XML

CONVERTIBLE NOTES PAYABLE

9 Months Ended

Sep. 30, 2016

Notes to Financial Statements

CONVERTIBLE NOTES PAYABLE

8. CONVERTIBLE NOTES PAYABLE

Convertible Notes Payable at consists of the following:	September 30,		December 31,
	2016		2015
$52,476 face value,10% unsecured note payable to an investor, note interest and principal are due on demand.  The note could be converted to option rights for the Company’s shares at ten cents per share ($0.10), these rights expired on January 12, 2010. The note is currently in default, but no penalties occur due to default.	$	28,476	$	28,476
Unamortized debt discount		-		-
Total, net of unamortized discount		28,476		28,476
$1,000,000 face value 9% secured notes payable to investors, due in 2015. At the investor’s option until the repayment date, the note and related interest may be converted to shares of the Company’s common stock a discount of 90% of the current share price after the first anniversary of the note. The notes are secured by the accounts receivable of a license agreement the Company has with Womens Choice Pharmaceuticals, LLC on its proprietary prescription product, ProCort®. The Company has determined the value associated with the beneficial conversion feature in connection with the notes and interest to be $111,110. The aggregate original issue discount feature has been accreted and charged to interest expenses as a financing expense. The original issue discount feature is valued under the intrinsic value method. The notes have reach maturity and are now in default, under the notes default provisions the entire balance is now due upon demand.		1,000,000		1,000,000
Original issue discount		111,110		111,110
Unamortized debt discount		-		-
Total, net of unamortized discount		1,111,110		1,111,110
On July 28, 2015, the Company entered into a convertible promissory note pursuant to which it borrowed $47,500. Interest under the convertible promissory note is 8% per annum, and the principal and all accrued but unpaid interest is due on April 30, 2016. The note is convertible at any time following 180 days after the issuance date at noteholders option into shares of our common stock at a variable conversion price of 58% of the lowest average three day market price of our common stock during the 10 trading days prior to the notice of conversion, subject to adjustment as described in the note. The holder’s ability to convert the note, however, is limited in that it will not be permitted to convert any portion of the note if the number of shares of our common stock beneficially owned by the holder and its affiliates, together with the number of shares of our common stock issuable upon any full or partial conversion, would exceed 9.99% of the Company’s outstanding shares of common stock. The Company has determined the value associated with the beneficial conversion feature in connection with the notes negotiated on July 28, 2015 to be $44,634. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $19,497 during the nine months ending September 30, 2016. The beneficial conversion feature is valued under the intrinsic value method During the nine months ending September 30, 2016, the Company paid $72,458 to the note holder to settle the note in full. The payment included interest and prepayment penalties of $24,958.		-		47,500
Unamortized debt discount		-		(19,497)
Total, net of unamortized discount		-		28,003
$135,000 face value 9% unsecured notes payable to investors, due October 26, 2017. At the investor’s option until the repayment date, the note and related interest may be converted to shares of the Company’s common stock a discount of 90% of the current share price after the first anniversary of the note. The notes are secured by the accounts receivable of a license agreement the Company has with Womens Choice Pharmaceuticals, LLC on its proprietary prescription product, ProCort®. The Company has determined the value associated with the beneficial conversion feature in connection with the notes and interest to be $117,535. The aggregate original issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $44,115 during the nine months ended September 30, 2016. The original issue discount feature is valued under the intrinsic value method.		135,000		135,000
Unamortized debt discount		(62,793)		(106,908)
Total, net of unamortized discount		72,207		28,092
On December 17, 2015, the Company entered into a convertible promissory note pursuant to which it borrowed $25,000. Interest under the convertible promissory note is 10% per annum, and the principal and all accrued but unpaid interest is due on May 17, 2016. The note is convertible into 1,250,000 shares of the Company’s common stock at a price of $0.02 per share and 625,000 warrants exercisable at $0.04 per share. The Company has determined the value associated with the beneficial conversion feature in connection with the notes negotiated on December 17, 2015 to be $16,648. The aggregate original issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $16,648 during the nine months ended September 30, 2016. The beneficial conversion feature is valued under the intrinsic value method The Note and all accrued interest was paid in full through the issuance of a new convertible note on August 31, 2016.		-		25,000
Unamortized debt discount		-		(15,104)
Total, net of unamortized discount		-		9,896
On February 1, 2016, the Company entered into a convertible promissory note pursuant to which it borrowed $25,000. Interest under the convertible promissory note is 10% per annum, and the principal and all accrued but unpaid interest is due on July 25, 2016. The note is convertible into 1,250,000 shares of the Company’s common stock at a price of $0.02 per share and 625,000 warrants exercisable at $0.02 per share. The Company has determined the value associated with the beneficial conversion feature in connection with the notes negotiated on February 1, 2016 to be $21,819. The aggregate original issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $21,819 during the nine months ended September 30, 2016. The beneficial conversion feature is valued under the intrinsic value method The Note and all accrued interest was paid in full through the issuance of a new convertible note on August 31, 2016.		-		-
Unamortized debt discount		-		-
Total, net of unamortized discount		-		-
On February 1, 2016, the Company entered into a convertible promissory note pursuant to which it borrowed $38,000. Interest under the convertible promissory note is 10% per annum, and the principal and all accrued but unpaid interest is due on February 15, 2017. The note is convertible into 1,900,000 shares of the Company’s common stock at a price of $0.02 per share and 950,000 warrants exercisable at $0.02 per share. The Company has determined the value associated with the beneficial conversion feature in connection with the notes negotiated on February 1, 2016 to be $33,164. The aggregate original issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $21,120 during the nine months ended September 30, 2016. The beneficial conversion feature is valued under the intrinsic value method		38,000		-
Unamortized debt discount		(12,044)		-
Total, net of unamortized discount		25,956		-
On February 17, 2016, the Company entered into a convertible promissory note pursuant to which it borrowed $20,000. Interest under the convertible promissory note is 9% per annum, and the principal and all accrued but unpaid interest is due on February 17, 2018. The note is convertible at any time following 90 days after the issuance date at noteholders option into shares of our common stock at a variable conversion price of 90% of the average five day market price of our common stock during the 5 trading days prior to the notice of conversion, subject to adjustment as described in the note. The holder’s ability to convert the note, however, is limited in that it will not be permitted to convert any portion of the note if the number of shares of our common stock beneficially owned by the holder and its affiliates, together with the number of shares of our common stock issuable upon any full or partial conversion, would exceed 4.99% of the Company’s outstanding shares of common stock. The Company has determined the value associated with the beneficial conversion feature in connection with the notes negotiated on February 27, 2016 to be $14,049. The aggregate original issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $4,349 during the nine months ended September 30, 2016. The beneficial conversion feature is valued under the intrinsic value method		20,000		-
Unamortized debt discount		(9,699)		-
Total, net of unamortized discount		10,301		-
On August 11, 2016, the Company entered into a convertible promissory note pursuant to which it borrowed $15,000. Interest under the convertible promissory note is 9% per annum, and the principal and all accrued but unpaid interest is due on August 11, 2018. The note is convertible into shares of our common stock at a variable conversion price of 90% of the average market price of our common stock during the 5 trading days prior to the notice of conversion, subject to adjustment as described in the note. The Company has determined the value associated with the beneficial conversion feature in connection with the notes negotiated on August 11, 2016 to be $14,728. The aggregate original issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $1,009 during the nine months ended September 30, 2016. The beneficial conversion feature is valued under the intrinsic value method		15,000		-
Unamortized debt discount		(13,719)		-
Total, net of unamortized discount		1,281		-
On August 31, 2016, the Company entered into a convertible promissory note pursuant to which it settled $50,000 in convertible notes and accrued interest of $3,404. Interest under the convertible promissory note is 10% per annum, and the principal and all accrued but unpaid interest is due on December 31, 2016. The note is convertible into 5,340,283 shares of the Company’s common stock at a price of $0.01 per share and 2,670,142 warrants exercisable at $0.02 per share. The Company has determined the value associated with the beneficial conversion feature in connection with the notes negotiated on August 31, 2016 to be $32,121. The aggregate original issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $7,899 during the nine months ended September 30, 2016. The beneficial conversion feature is valued under the intrinsic value method		53,404		-
Unamortized debt discount		(24,222)		-
Total, net of unamortized discount		29,182		-
	$	1,278,813	$	1,205,576

XML

CONVERTIBLE NOTES PAYABLE RELATED PARTY

9 Months Ended

Sep. 30, 2016

Notes to Financial Statements

CONVERTIBLE NOTES PAYABLE RELATED PARTY

9. CONVERTIBLE NOTES PAYABLE RELATED PARTY

Convertible Notes Payable Related Party at consists of the following:	September 30,		December 31,
	2016		2015
On December 31, 2011, the Company re-negotiated accrued salaries and interest for three employees. Under the terms of the agreements, the notes dated before December 31, 2010, and all salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.04 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.06 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes negotiated on December 31, 2011 to be $1,123,078. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $125,048 during the nine months ending September 30, 2016.  The beneficial conversion feature is valued under the intrinsic value method.  In the year ending December 2013, the Company  made $51,485 in cash payments to reduce the note balance.		1,071,593		1,071,593
Unamortized debt discount		(41,921)		(166,969)
On June 30, 2012, the Company re-negotiated accrued salaries and interest for three employees. Under the terms of the agreements, the notes dated before July 1, 2011, and all salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.04 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.06 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the  notes to be $209,809. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $31,212 during the nine months ending September 30, 2016.  The beneficial conversion feature is valued under the intrinsic value method.  On January 18, 2013, the Company  made a $3,990 cash payment to reduce the note balance.		321,032		321,032
Unamortized debt discount		(31,098)		(62,310)
On December 30 and 31, 2012, the Company re-negotiated accrued salaries and interest for three employees. Under the terms of the agreements, $182,083 of related party notes accrued interest and salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $182,083 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.03 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.04 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $182,083. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $27,323 during the nine months ending September 30, 2016.  The beneficial conversion feature is valued under the intrinsic value method.		182,083		182,083
Unamortized debt discount		(45,558)		(72,881)
On June 30, 2013, the Company re-negotiated accrued salaries and interest for two employees. Under the terms of the agreements, $106,153 of accrued interest and salaries were converted to promissory notes convertible into common stock with a warrant feature. The $106,153 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.03 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.04 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $70,768. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $10,619 during the nine months ending September 30, 2016.  The beneficial conversion feature is valued under the intrinsic value method.		106,152		106,152
Unamortized debt discount		(24,726)		(35,345)
On December 31, 2013, the Company re-negotiated accrued salaries and interest for three employees. Under the terms of the agreements, $142,501 of accrued interest and salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $142,501 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.03 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.04 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $94,909. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $14,241 during nine months ending September 30, 2016. The beneficial conversion feature is valued under the intrinsic value method.		142,501		142,501
Unamortized debt discount		(42,725)		(56,966)
On June 30, 2014, the Company re-negotiated accrued salaries and interest for three employees. Under the terms of the agreements, $118,126 of accrued salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $118,126 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.025 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.03 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $118,126. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $17,725 during the nine months ending September 30, 2016. The beneficial conversion feature is valued under the intrinsic value method.		118,126		118,126
Unamortized debt discount		(64,885)		(82,610)
On September 30, 2014, the Company re-negotiated accrued salaries and interest for two employees. Under the terms of the agreements, $40,558 of accrued salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $40,558 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.04 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.05 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $40,466. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $6,072 during nine months ending September 30, 2016. The beneficial conversion feature is valued under the intrinsic value method.		40,558		40,558
Unamortized debt discount		(24,266)		(30,338)
On December 31, 2014, the Company re-negotiated accrued salaries and interest for two employees. Under the terms of the agreements, $65,295 of accrued salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $65,295 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.04 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.05 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $57,439. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $8,619 during the nine months ending September 30, 2016. The beneficial conversion feature is valued under the intrinsic value method.		65,295		65,295
Unamortized debt discount		(37,338)		(45,957)
On December 31, 2015, the Company re-negotiated accrued salaries and interest for three employees and a director. Under the terms of the agreements, $343,687 of accrued salaries and director fees not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $343,687 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.02 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.02 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $341,703. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $51,247 during the nine months ending September 30, 2016. The beneficial conversion feature is valued under the intrinsic value method.		343,687		343,687
Unamortized debt discount		(290,456)		(341,703)
On March 30, 2016, the Company re-negotiated accrued directors fees of 3,600. Under the terms of the agreements, $3,600 of accrued director fees not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $3,600 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.02 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.02 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $864. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $110 during the nine months ending September 30, 2016. The beneficial conversion feature is valued under the intrinsic value method.		3,600		-
Unamortized debt discount		(764)		-
On April 30, 2016, the Company re-negotiated accrued salaries and interest for an employee. Under the terms of the agreements, $33,333 of accrued salaries were converted to promissory notes convertible into common stock with a warrant feature. The $33,333 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.02 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.02 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $8,401. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $620 during the nine months ending September 30, 2016. The beneficial conversion feature is valued under the intrinsic value method.		33,333		-
Unamortized debt discount		(7,781)		-
On June 30, 2016, the Company re-negotiated accrued salaries and interest for three employees. Under the terms of the agreements, $192,417 of accrued salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $192,417 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.02 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.02 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $28,365. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $1,429 during the nine months ending September 30, 2016.  The beneficial conversion feature is valued under the intrinsic value method.		192,417		-
Unamortized debt discount		(26,936)		-
On July 8, 2016, the Company re-negotiated accrued salaries and interest for one employee. Under the terms of the agreement, $2,000 of accrued salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $2,000 face value promissory notes are unsecured, due on December 31, 2021, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.01 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.02 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $1,012. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $42 during the nine months ending September 30, 2016. The beneficial conversion feature is valued under the intrinsic value method.		2000		-
Unamortized debt discount		(970)		-
On September 30, 2016, the Company re-negotiated accrued directors fees of 3,600. Under the terms of the agreements, $3,600 of accrued director fees not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $3,600 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.01 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.02 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $1,571. The aggregate beneficial conversion feature will be accreted and charged to interest expenses as a financing expense. The beneficial conversion feature is valued under the intrinsic value method.		3,600		-
Unamortized debt discount		(1,571)		-
	$	1,984,982	$	1,495,948

XML

STOCKHOLDERS DEFICIT

9 Months Ended

Sep. 30, 2016

Equity [Abstract]

STOCKHOLDERS DEFICIT

10. STOCKHOLDERS’ DEFICIT

The Company is authorized to issue 200,000,000 shares of $0.001 par value common stock. The Company had 119,573,969 and 115,701,969 issued and outstanding shares of common stock as of September 30, 2016 and December 31, 2015, respectively.

On September 13, 2016, 2,500,000 shares of the Company’s common stock and 1,000,000 warrants exercisable at $0.02 were issued for a cash investment of $25,000.

On March 30, 2016, 72,000 shares of the Company’s common stock were issued to settle $3,600 of accrued expenses due to a director of the Company. A gain of $2.592 was recognized as a result of this settlement.

On January 27, 2016, the Company entered into a promissory note and pursuant to its terms the Company issued the holder 100,000 shares of its common stock valued at $0.02 per share. The shares were fair valued at $2,000 or $0.02 per   share.

On January 27, 2016, the Company entered into a promissory note and pursuant to its terms the Company issued the holder 200,000 shares of its common stock valued at $0.02 per share. The shares were fair valued at $4,980 or $0.0249 per share.

On February 1, 2016, the Company entered into a promissory note and pursuant to its terms the Company issued the holder 400,000 shares of its common stock valued at $0.02 per share. The shares were fair valued at $9,960 or $0.0249 per share.

On February 1, 2016, the Company entered into a promissory note and pursuant to its terms the Company issued the holder 250,000 shares of its common stock valued at $0.02 per share.   The shares were fair valued at $6,225 or $0.0249 per share.

On February 2, 2016, the Company issued of 400,000 shares of the Company’s common stock to five consultants for services related to the Company’s financing. The shares were fair valued at $9,960 or $0.0249 per share.

XML

COMMITMENTS AND CONTINGENCIES

9 Months Ended

Sep. 30, 2016

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

11. COMMITMENTS AND CONTINGENCIES

Lease obligations – The Company has operating leases for its offices. Future minimum lease payments under the operating leases for the facilities as of September 30, 2016, are as follows:

2016 8,576

2017 5,718

Rental expense, resulting from operating lease agreements, approximated $32,358 and $32,619 for the nine months ended September 30, 2016 and 2015, respectively.

On April 1, 2016, the Company licensed to Kintari Int. Inc. the following: the exclusive rights to its existing line of cosmeceutical products; the exclusive rights to any future cosmeceutical products developed by the Company; the right-of-first-refusal on its existing OTC products; and the right-of-first-refusal to any future OTC products developed by the Company. In exchange, the Company acquired 8,000,000 shares of Kintari Int. Inc.’s common stock. Kintari Int. Inc. is the Company’s wholly owned subsidiary. The material terms of the license with Skinvisible are as follows:

•  Kintari acquired the right to appoint sub-licensees provided that Skinvisible approves in advance.

• If Skinvisible desires to sell an OTC product, it must first notify Kintari. If Kintari desires to exercise the right-of-first-refusal on that OTC product, Kintari must launch the product within 6 months or lose it to Skinvisible.

• Kintari agreed to purchase the existing product inventory, raw ingredients, packaging materials plus all Kintari marketing materials for a total of $87,720.14. Kintari has not yet paid this amount and the parties are waiting for fundraising in connection with an offering to do so.

•  Skinvisible agreed to sell its polymers to Kintari and Kintari will manufacture the products using those polymers.

•  Kintari may use any of Skinvisible’s existing trademarks.

•  Kintari agreed to pay to Skinvisible an on-going royalty of 5% on revenue generated from the products.

•  Kintari agreed to pay to Skinvisible a minimum annual royalty equal to $50,000 for the first year after launch, $100,000 for the second year after launch and $150,000 for the third year after launch and each subsequent year for the term of the agreement.

•  Kintari agreed to pay to Skinvisible a royalty of 25% of any non-royalty payments received by Kintari from sub-licensees, including fees received in consideration for sublicensing the products.

•  The agreement may be terminated by, among other things, a mutual consent of the parties or a breach and failure to cure by one of the parties.

SKINVISIBLE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Kintari Int. Inc. commenced business in April 2016 in the U.S. and expects to begin operations in Canada in September 2016. Kintari Int. Inc. is the parent company to Kintari USA Inc. and Kintai Canana Inc. These companies will be used as operating entities to market and sell the products. Kintari Int. Inc. will need to raise capital of at least $2 million to assist with its development and payments to the Company. Kintari Int. Inc. plans to seek a TSX Venture Exchange listing upon completion of this financing.

XML

SUBSEQUENT EVENTS

9 Months Ended

Sep. 30, 2016

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

12.    SUBSEQUENT EVENTS

On October 20, 2016, the Company re-negotiated accrued salaries and interest for an employee. Under the terms of the agreement, $18,000 of accrued salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The Company also refinanced $89,340 in notes issued in 2010 and 2011 through the issuance of a the new note. The $111,056 face value promissory note is unsecured, due on December 31, 2016, and bears an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.01 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.02 per share for three years after the conversion date.

On October 20, 2016, the Company re-negotiated $328,481 in unsecured notes payable for an employee. Under the terms of the original agreement, the promissory note was due on December 31, 2016, bears an interest rate of 10% and at the investor’s option until the repayment date, the note could be converted to shares of the Company’s common stock at a fixed price of $0.04 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.06 per share for three years after the conversion date. Under the modified terms that $328,481 face value note is now due on December 31, 2019, bears an interest rate of 10% and at the investor’s option until the repayment date, the note can be converted to shares of the Company’s common stock at a fixed price of $0.01 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.02 per share for three years after the conversion date.

On October 20, 2016, the Company re-negotiated $179,678 in unsecured notes payable for an employee. Under the terms of the original agreement, the promissory note was due on December 31, 2016, bears an interest rate of 10% and at the investor’s option until the repayment date, the note could be converted to shares of the Company’s common stock at a fixed price of $0.04 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.06 per share for three years after the conversion date. Under the modified terms that $179,678 face value note is now due on December 31, 2019, bears an interest rate of 10% and at the investor’s option until the repayment date, the note can be converted to shares of the Company’s common stock at a fixed price of $0.01 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.02 per share for three years after the conversion date.

On October 20, 2016, the Company re-negotiated $58,437 in unsecured notes payable for an employee. Under the terms of the original agreement, the promissory note was due on December 31, 2016, bears an interest rate of 10% and at the investor’s option until the repayment date, the note could be converted to shares of the Company’s common stock at a fixed price of $0.04 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.06 per share for three years after the conversion date. Under the modified terms that $58,437 face value note is now due on December 31, 2019, bears an interest rate of 10% and at the investor’s option until the repayment date, the note can be converted to shares of the Company’s common stock at a fixed price of $0.01 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.02 per share for three years after the conversion date.

On October 20, 2016, the Company re-negotiated $415,657 in unsecured notes payable for an employee. Under the terms of the original agreement, the promissory note was due on December 31, 2016, bears an interest rate of 10% and at the investor’s option until the repayment date, the note could be converted to shares of the Company’s common stock at a fixed price of $0.04 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.06 per share for three years after the conversion date. Under the modified terms that $415,657 face value note is now due on December 31, 2019, bears an interest rate of 10% and at the investor’s option until the repayment date, the note can be converted to shares of the Company’s common stock at a fixed price of $0.01 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.02 per share for three years after the conversion date.

On October 8, 2016, the Company entered into a 10% unsecured note payable to an employee and received total proceeds of $5,070. The note is due on December 31, 2016.

On October 11, 2016, the Company entered into a 10% unsecured note payable to an employee and received total proceeds of $5,000. The note is due on December 31, 2016.

On October 31, 2016, 3,333,350 shares of the Company’s common stock and 1,666,675 warrants exercisable at $0.025 were issued for a cash investment of $50,000.

XML

DESCRIPTION OF BUSINESS, HISTORY AND SUMMARY OF SIGNIFICANT POLICIES (Policies)

9 Months Ended

Sep. 30, 2016

Accounting Policies [Abstract]

Description of Business

Description of business – Skinvisible, Inc., (referred to as the “Company”) is focused on the development and manufacture and sales of innovative topical, transdermal and mucosal polymer-based delivery system technologies and formulations incorporating its patent-pending formula/process for combining hydrophilic and hydrophobic polymer emulsions. The technologies and formulations have broad industry applications within the pharmaceutical, over-the-counter, personal skincare and cosmetic arenas. Additionally, the Company’s non-dermatological formulations, offer solutions for a broad spectrum of markets women’s health, pain management, and others. The Company maintains executive and sales offices in Las Vegas, Nevada.

History

History – The Company was incorporated in Nevada on March 6, 1998, under the name of Microbial Solutions, Inc. The Company underwent a name change on February 26, 1999, when it changed its name to Skinvisible, Inc. The Company’s subsidiary’s name of Manloe Labs, Inc. was also changed to Skinvisible Pharmaceuticals, Inc.

On September 9, 2014, the Company formed Kinatri USA Inc., a wholly-owned subsidiary, to market a premium line of scientifically formulated skincare products powered by our patented Invisicare® technology. As part of its strategic focus on revenue generation and creating shareholder value, Kintari USA Inc. products will be sold via network marketing.

The Kintari product portfolio consists of anti-aging products to help fight the signs of aging. These products have been developed using proven anti-aging ingredients with scientific evidence of their effectiveness at reducing the look of fine lines and wrinkles resulting in youthful looking skin. These potent ingredients will be powered by patented Invisicare technology, providing consumers with unique, effective products which the Company believes cannot be duplicated. Additional products will be added to enhance this product line as the Company grows and expands.

Skinvisible, Inc., together with its subsidiaries, shall herein be collectively referred to as the “Company.”

Going Concern

Going concern – The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred cumulative net losses of $29,408,625 since its inception and requires capital for its contemplated operational and marketing activities to take place. The Company’s ability to raise additional capital through the future issuances of common stock is unknown. The obtainment of additional financing, the successful development of the Company’s contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. The ability to successfully resolve these factors raise substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.

Principles of Consolidation

Principles of consolidation – The consolidated financial statements include the accounts of the Company and its subsidiaries. All significant intercompany balances and transactions have been eliminated.

Use of Estimates

Use of estimates – The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Cash and Cash Equivalents

Cash and cash equivalents

For purposes of the statement of cash flows, the Company considers all highly liquid investments and short-term debt instruments with original maturities of three months or less to be cash equivalents. There are $0 and $0 in cash and cash equivalents as of September 30, 2016 and December 31, 2015, respectively.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

The carrying amounts reflected in the balance sheets for cash, accounts payable and accrued expenses approximate the respective fair values due to the short maturities of these items.

As required by the Fair Value Measurements and Disclosures Topic of the FASB ASC, fair value is measured based on a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: (Level 1) observable inputs such as quoted prices in active markets; (Level 2) inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and (Level 3) unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

The three levels of the fair value hierarchy are described below:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability;

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).

Revenue Recognition

Revenue recognition

Product sales – Revenues from the sale of products (Invisicare® polymers) are recognized when title to the products are transferred to the customer and only when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive reasonably assured payments for products sold and delivered.

Royalty sales – The Company also recognizes royalty revenue from licensing its patented product formulations only when earned, when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments.

Distribution and license rights sales – The Company also recognizes revenue from distribution and license rights only when earned (and are amortized over a five year period), when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments.

Costs of Revenue – Cost of revenue includes raw materials, component parts, and shipping supplies. Shipping and handling costs is not a significant portion of the cost of revenue.

Accounts Receivable

Accounts Receivable – Accounts receivable is comprised of uncollateralized customer obligations due under normal trade terms requiring payment within 30 days from the invoice date. The carrying amount of accounts receivable is reviewed periodically for collectability. If management determines that collection is unlikely, an allowance that reflects management’s best estimate of the amounts that will not be collected is recorded. Management reviews each accounts receivable balance that exceeds 30 days from the invoice date and, based on an assessment of creditworthiness, estimates the portion, if any, of the balance that will not be collected. As of September 30, 2016, the Company had not recorded a reserve for doubtful accounts. The Company has $1,135,000 in convertible notes payable which are secured by the accounts receivable of a license agreement the Company has with Women's Choice Pharmaceuticals, LLC on its proprietary prescription product, ProCort®.

Inventory

Inventory – Substantially all inventory consists of finished goods and are valued based upon first-in first-out ("FIFO") cost, not in excess of market. The determination of whether the carrying amount of inventory requires a write-down is based on an evaluation of inventory.

Goodwill and Intangible Assets

Goodwill and intangible assets – The Company follows Financial Accounting Standard Board’s (FASB) Codification Topic 350-10 (“ASC 350-10”), “Intangibles – Goodwill and Other”. According to this statement, goodwill and intangible assets with indefinite lives are no longer subject to amortization, but rather an annual assessment of impairment by applying a fair-value based test. Fair value for goodwill is based on discounted cash flows, market multiples and/or appraised values as appropriate. Under ASC 350-10, the carrying value of assets are calculated at the lowest level for which there are identifiable cash flows.

Income Taxes

Income taxes – The Company accounts for its income taxes in accordance with FASB Codification Topic ASC 740-10, “Income Taxes”, which requires recognition of deferred tax assets and liabilities for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

Stock-based Compensation

Stock-based compensation – The Company follows the guidelines in FASB Codification Topic ASC 718-10 “Compensation-Stock Compensation”, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and directors including employee stock options and employee stock purchases related to an Employee Stock Purchase Plan based on the estimated fair values.

Earnings (loss) Per Share

Earnings (loss) per share – The Company reports earnings (loss) per share in accordance with FASB Codification Topic ASC 260-10 “Earnings Per Share”, Basic earnings (loss) per share is computed by dividing income (loss) available to common shareholders by the weighted average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted earnings (loss) per share has not been presented since the effect of the assumed exercise of options and warrants to purchase common shares (common stock equivalents) would have an anti-dilutive effect.

XML

FIXED ASSETS (Tables)

9 Months Ended

Sep. 30, 2016

Property, Plant and Equipment [Abstract]

Schedule of Property and Plan Equipment

Fixed assets consist of the following as of September 30, 2016 and December 31, 2015:

		September 30, 2016		December 31, 2015
Machinery and equipment	$	48,163	$	48,163
Furniture and fixtures		113,635		113,635
Computers, equipment and software		39,722		39,722
Leasehold improvements		12,569		12,569
Lab equipment		113,461		113,461
Total		327,550		327,550
Less: accumulated depreciation		(326,786)		(325,855)
Fixed assets, net of accumulated depreciation	$	764	$	1,695

XML

INVENTORY (Tables)

9 Months Ended

Sep. 30, 2016

Inventory Disclosure [Abstract]

Schedule of Inventory

		September 30, 2016		December 31, 2015
Shipping and Packing materials	$	10,392	$	11,651
Marketing Supplies		17,322		19,346
Finished Goods		34,227		19,082
Raw Materials		19,811		40,893
Total	$	81,752	$	90,972

XML

STOCK OPTIONS AND WARRANTS (Tables)

9 Months Ended

Sep. 30, 2016

Temporary Equity Disclosure [Abstract]

Summary of Options

	Number of Shares		Weighted Average Exercise Price
Balance, December 31, 2015		8.450.000	$	0.05
Options granted and assumed		4,150,000	$	0.02
Options expired		1,350,000	$	0.04
Options canceled		—		—
Options exercised		—		—
Balance, September 30, 2016		11,250,000	$	0.03

Summary of Warrants

	Number of Shares		Weighted Average Exercise Price
Balance, December 31, 2015		2,969,750	$	0.06
Warrants granted and assumed		1,661,000		0.02
Warrants expired		1,344,750		0.06
Warrants canceled		—		—
Warrants exercised		—		—
Balance, September 30, 2016		3,286,000	$	0.04

XML

CONVERTIBLE NOTES PAYABLE (Tables)

9 Months Ended

Sep. 30, 2016

Notes to Financial Statements

Schedule of Conversions of Stock

Convertible Notes Payable at consists of the following:	September 30,		December 31,
	2016		2015
$52,476 face value,10% unsecured note payable to an investor, note interest and principal are due on demand.  The note could be converted to option rights for the Company’s shares at ten cents per share ($0.10), these rights expired on January 12, 2010. The note is currently in default, but no penalties occur due to default.	$	28,476	$	28,476
Unamortized debt discount		-		-
Total, net of unamortized discount		28,476		28,476
$1,000,000 face value 9% secured notes payable to investors, due in 2015. At the investor’s option until the repayment date, the note and related interest may be converted to shares of the Company’s common stock a discount of 90% of the current share price after the first anniversary of the note. The notes are secured by the accounts receivable of a license agreement the Company has with Womens Choice Pharmaceuticals, LLC on its proprietary prescription product, ProCort®. The Company has determined the value associated with the beneficial conversion feature in connection with the notes and interest to be $111,110. The aggregate original issue discount feature has been accreted and charged to interest expenses as a financing expense. The original issue discount feature is valued under the intrinsic value method. The notes have reach maturity and are now in default, under the notes default provisions the entire balance is now due upon demand.		1,000,000		1,000,000
Original issue discount		111,110		111,110
Unamortized debt discount		-		-
Total, net of unamortized discount		1,111,110		1,111,110
On July 28, 2015, the Company entered into a convertible promissory note pursuant to which it borrowed $47,500. Interest under the convertible promissory note is 8% per annum, and the principal and all accrued but unpaid interest is due on April 30, 2016. The note is convertible at any time following 180 days after the issuance date at noteholders option into shares of our common stock at a variable conversion price of 58% of the lowest average three day market price of our common stock during the 10 trading days prior to the notice of conversion, subject to adjustment as described in the note. The holder’s ability to convert the note, however, is limited in that it will not be permitted to convert any portion of the note if the number of shares of our common stock beneficially owned by the holder and its affiliates, together with the number of shares of our common stock issuable upon any full or partial conversion, would exceed 9.99% of the Company’s outstanding shares of common stock. The Company has determined the value associated with the beneficial conversion feature in connection with the notes negotiated on July 28, 2015 to be $44,634. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $19,497 during the nine months ending September 30, 2016. The beneficial conversion feature is valued under the intrinsic value method During the nine months ending September 30, 2016, the Company paid $72,458 to the note holder to settle the note in full. The payment included interest and prepayment penalties of $24,958.		-		47,500
Unamortized debt discount		-		(19,497)
Total, net of unamortized discount		-		28,003
$135,000 face value 9% unsecured notes payable to investors, due October 26, 2017. At the investor’s option until the repayment date, the note and related interest may be converted to shares of the Company’s common stock a discount of 90% of the current share price after the first anniversary of the note. The notes are secured by the accounts receivable of a license agreement the Company has with Womens Choice Pharmaceuticals, LLC on its proprietary prescription product, ProCort®. The Company has determined the value associated with the beneficial conversion feature in connection with the notes and interest to be $117,535. The aggregate original issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $44,115 during the nine months ended September 30, 2016. The original issue discount feature is valued under the intrinsic value method.		135,000		135,000
Unamortized debt discount		(62,793)		(106,908)
Total, net of unamortized discount		72,207		28,092
On December 17, 2015, the Company entered into a convertible promissory note pursuant to which it borrowed $25,000. Interest under the convertible promissory note is 10% per annum, and the principal and all accrued but unpaid interest is due on May 17, 2016. The note is convertible into 1,250,000 shares of the Company’s common stock at a price of $0.02 per share and 625,000 warrants exercisable at $0.04 per share. The Company has determined the value associated with the beneficial conversion feature in connection with the notes negotiated on December 17, 2015 to be $16,648. The aggregate original issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $16,648 during the nine months ended September 30, 2016. The beneficial conversion feature is valued under the intrinsic value method The Note and all accrued interest was paid in full through the issuance of a new convertible note on August 31, 2016.		-		25,000
Unamortized debt discount		-		(15,104)
Total, net of unamortized discount		-		9,896
On February 1, 2016, the Company entered into a convertible promissory note pursuant to which it borrowed $25,000. Interest under the convertible promissory note is 10% per annum, and the principal and all accrued but unpaid interest is due on July 25, 2016. The note is convertible into 1,250,000 shares of the Company’s common stock at a price of $0.02 per share and 625,000 warrants exercisable at $0.02 per share. The Company has determined the value associated with the beneficial conversion feature in connection with the notes negotiated on February 1, 2016 to be $21,819. The aggregate original issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $21,819 during the nine months ended September 30, 2016. The beneficial conversion feature is valued under the intrinsic value method The Note and all accrued interest was paid in full through the issuance of a new convertible note on August 31, 2016.		-		-
Unamortized debt discount		-		-
Total, net of unamortized discount		-		-
On February 1, 2016, the Company entered into a convertible promissory note pursuant to which it borrowed $38,000. Interest under the convertible promissory note is 10% per annum, and the principal and all accrued but unpaid interest is due on February 15, 2017. The note is convertible into 1,900,000 shares of the Company’s common stock at a price of $0.02 per share and 950,000 warrants exercisable at $0.02 per share. The Company has determined the value associated with the beneficial conversion feature in connection with the notes negotiated on February 1, 2016 to be $33,164. The aggregate original issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $21,120 during the nine months ended September 30, 2016. The beneficial conversion feature is valued under the intrinsic value method		38,000		-
Unamortized debt discount		(12,044)		-
Total, net of unamortized discount		25,956		-
On February 17, 2016, the Company entered into a convertible promissory note pursuant to which it borrowed $20,000. Interest under the convertible promissory note is 9% per annum, and the principal and all accrued but unpaid interest is due on February 17, 2018. The note is convertible at any time following 90 days after the issuance date at noteholders option into shares of our common stock at a variable conversion price of 90% of the average five day market price of our common stock during the 5 trading days prior to the notice of conversion, subject to adjustment as described in the note. The holder’s ability to convert the note, however, is limited in that it will not be permitted to convert any portion of the note if the number of shares of our common stock beneficially owned by the holder and its affiliates, together with the number of shares of our common stock issuable upon any full or partial conversion, would exceed 4.99% of the Company’s outstanding shares of common stock. The Company has determined the value associated with the beneficial conversion feature in connection with the notes negotiated on February 27, 2016 to be $14,049. The aggregate original issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $4,349 during the nine months ended September 30, 2016. The beneficial conversion feature is valued under the intrinsic value method		20,000		-
Unamortized debt discount		(9,699)		-
Total, net of unamortized discount		10,301		-
On August 11, 2016, the Company entered into a convertible promissory note pursuant to which it borrowed $15,000. Interest under the convertible promissory note is 9% per annum, and the principal and all accrued but unpaid interest is due on August 11, 2018. The note is convertible into shares of our common stock at a variable conversion price of 90% of the average market price of our common stock during the 5 trading days prior to the notice of conversion, subject to adjustment as described in the note. The Company has determined the value associated with the beneficial conversion feature in connection with the notes negotiated on August 11, 2016 to be $14,728. The aggregate original issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $1,009 during the nine months ended September 30, 2016. The beneficial conversion feature is valued under the intrinsic value method		15,000		-
Unamortized debt discount		(13,719)		-
Total, net of unamortized discount		1,281		-
On August 31, 2016, the Company entered into a convertible promissory note pursuant to which it settled $50,000 in convertible notes and accrued interest of $3,404. Interest under the convertible promissory note is 10% per annum, and the principal and all accrued but unpaid interest is due on December 31, 2016. The note is convertible into 5,340,283 shares of the Company’s common stock at a price of $0.01 per share and 2,670,142 warrants exercisable at $0.02 per share. The Company has determined the value associated with the beneficial conversion feature in connection with the notes negotiated on August 31, 2016 to be $32,121. The aggregate original issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $7,899 during the nine months ended September 30, 2016. The beneficial conversion feature is valued under the intrinsic value method		53,404		-
Unamortized debt discount		(24,222)		-
Total, net of unamortized discount		29,182		-
	$	1,278,813	$	1,205,576

XML

CONVERTIBLE NOTES PAYABLE RELATED PARTY (Tables)

9 Months Ended

Sep. 30, 2016

Notes to Financial Statements

Convertible Notes Payable Related Party Disclosure

Convertible Notes Payable Related Party at consists of the following:	September 30,		December 31,
	2016		2015
On December 31, 2011, the Company re-negotiated accrued salaries and interest for three employees. Under the terms of the agreements, the notes dated before December 31, 2010, and all salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.04 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.06 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes negotiated on December 31, 2011 to be $1,123,078. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $125,048 during the nine months ending September 30, 2016.  The beneficial conversion feature is valued under the intrinsic value method.  In the year ending December 2013, the Company  made $51,485 in cash payments to reduce the note balance.		1,071,593		1,071,593
Unamortized debt discount		(41,921)		(166,969)
On June 30, 2012, the Company re-negotiated accrued salaries and interest for three employees. Under the terms of the agreements, the notes dated before July 1, 2011, and all salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.04 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.06 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the  notes to be $209,809. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $31,212 during the nine months ending September 30, 2016.  The beneficial conversion feature is valued under the intrinsic value method.  On January 18, 2013, the Company  made a $3,990 cash payment to reduce the note balance.		321,032		321,032
Unamortized debt discount		(31,098)		(62,310)
On December 30 and 31, 2012, the Company re-negotiated accrued salaries and interest for three employees. Under the terms of the agreements, $182,083 of related party notes accrued interest and salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $182,083 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.03 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.04 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $182,083. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $27,323 during the nine months ending September 30, 2016.  The beneficial conversion feature is valued under the intrinsic value method.		182,083		182,083
Unamortized debt discount		(45,558)		(72,881)
On June 30, 2013, the Company re-negotiated accrued salaries and interest for two employees. Under the terms of the agreements, $106,153 of accrued interest and salaries were converted to promissory notes convertible into common stock with a warrant feature. The $106,153 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.03 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.04 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $70,768. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $10,619 during the nine months ending September 30, 2016.  The beneficial conversion feature is valued under the intrinsic value method.		106,152		106,152
Unamortized debt discount		(24,726)		(35,345)
On December 31, 2013, the Company re-negotiated accrued salaries and interest for three employees. Under the terms of the agreements, $142,501 of accrued interest and salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $142,501 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.03 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.04 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $94,909. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $14,241 during nine months ending September 30, 2016. The beneficial conversion feature is valued under the intrinsic value method.		142,501		142,501
Unamortized debt discount		(42,725)		(56,966)
On June 30, 2014, the Company re-negotiated accrued salaries and interest for three employees. Under the terms of the agreements, $118,126 of accrued salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $118,126 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.025 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.03 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $118,126. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $17,725 during the nine months ending September 30, 2016. The beneficial conversion feature is valued under the intrinsic value method.		118,126		118,126
Unamortized debt discount		(64,885)		(82,610)
On September 30, 2014, the Company re-negotiated accrued salaries and interest for two employees. Under the terms of the agreements, $40,558 of accrued salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $40,558 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.04 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.05 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $40,466. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $6,072 during nine months ending September 30, 2016. The beneficial conversion feature is valued under the intrinsic value method.		40,558		40,558
Unamortized debt discount		(24,266)		(30,338)
On December 31, 2014, the Company re-negotiated accrued salaries and interest for two employees. Under the terms of the agreements, $65,295 of accrued salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $65,295 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.04 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.05 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $57,439. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $8,619 during the nine months ending September 30, 2016. The beneficial conversion feature is valued under the intrinsic value method.		65,295		65,295
Unamortized debt discount		(37,338)		(45,957)
On December 31, 2015, the Company re-negotiated accrued salaries and interest for three employees and a director. Under the terms of the agreements, $343,687 of accrued salaries and director fees not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $343,687 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.02 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.02 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $341,703. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $51,247 during the nine months ending September 30, 2016. The beneficial conversion feature is valued under the intrinsic value method.		343,687		343,687
Unamortized debt discount		(290,456)		(341,703)
On March 30, 2016, the Company re-negotiated accrued directors fees of 3,600. Under the terms of the agreements, $3,600 of accrued director fees not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $3,600 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.02 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.02 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $864. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $110 during the nine months ending September 30, 2016. The beneficial conversion feature is valued under the intrinsic value method.		3,600		-
Unamortized debt discount		(764)		-
On April 30, 2016, the Company re-negotiated accrued salaries and interest for an employee. Under the terms of the agreements, $33,333 of accrued salaries were converted to promissory notes convertible into common stock with a warrant feature. The $33,333 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.02 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.02 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $8,401. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $620 during the nine months ending September 30, 2016. The beneficial conversion feature is valued under the intrinsic value method.		33,333		-
Unamortized debt discount		(7,781)		-
On June 30, 2016, the Company re-negotiated accrued salaries and interest for three employees. Under the terms of the agreements, $192,417 of accrued salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $192,417 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.02 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.02 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $28,365. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $1,429 during the nine months ending September 30, 2016.  The beneficial conversion feature is valued under the intrinsic value method.		192,417		-
Unamortized debt discount		(26,936)		-
On July 8, 2016, the Company re-negotiated accrued salaries and interest for one employee. Under the terms of the agreement, $2,000 of accrued salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $2,000 face value promissory notes are unsecured, due on December 31, 2021, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.01 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.02 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $1,012. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $42 during the nine months ending September 30, 2016. The beneficial conversion feature is valued under the intrinsic value method.		2000		-
Unamortized debt discount		(970)		-
On September 30, 2016, the Company re-negotiated accrued directors fees of 3,600. Under the terms of the agreements, $3,600 of accrued director fees not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The $3,600 face value promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.01 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.02 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $1,571. The aggregate beneficial conversion feature will be accreted and charged to interest expenses as a financing expense. The beneficial conversion feature is valued under the intrinsic value method.		3,600		-
Unamortized debt discount		(1,571)		-
	$	1,984,982	$	1,495,948

XML

DESCRIPTION OF BUSINESS, HISTORY AND SUMMARY OF SIGNIFICANT POLICIES (Details Narrative) - USD ($)	9 Months Ended			12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2015
Accounting Policies [Abstract]
Date of Incorporation	Mar. 06, 1998
Accumulated Deficit	$ (29,408,625)				$ (27,831,352)
Cash	0				$ 0
Stock based compenstation	133,445	$ 8,800	$ 31,050	$ 54,450
Convertible Notes Payable	$ 1,135,000

XML

FIXED ASSETS - Schedule of Property and Plan Equipment (Details) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Machinery and equipment	$ 48,163	$ 48,163
Furniture and fixtures	113,635	113,635
Computers, equipment and software	39,722	39,722
Leasehold improvements	12,569	12,569
Lab equipment	113,461	113,461
Total	327,550	327,550
Less: accumulated depreciation	(326,786)	(325,855)
Fixed assets, net of accumulated depreciation	$ 764	$ 1,695

XML

FIXED ASSETS (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 931	$ 1,185

XML

INVENTORY - Schedule of Inventory (Details) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Inventory Disclosure [Abstract]
Shipping and Packing Materials	$ 10,392	$ 11,651
Marketing Supplies	17,322	19,346
Finished Goods	34,227	19,082
Raw Materials	19,811	40,893
Total	$ 81,752	$ 90,972

XML

INTANGIBLE AND OTHER ASSETS (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Notes to Financial Statements
Patents and trademarks, Gross	$ 646,169
Accumulated Amortization	386,851		$ 344,451
Amortization Expense	$ 42,400	$ 42,192

XML

STOCK OPTIONS AND WARRANTS - Summary of Options (Details)	9 Months Ended
	Sep. 30, 2016 $ / shares shares
Stock Options And Warrants - Summary Of Options Details
Beginning Balance, number of shares | shares	8,450,000
Beginning Balance, weighted average exercise price | $ / shares	$ 0.05
Options granted and assumed, number of shares | shares	4,150,000
Options granted and assumed, weighted average exercise price | $ / shares	$ 0.02
Options expired, number of shares | shares	1,350,000
. | $ / shares	$ 0.04
Ending Balance, number of shares | shares	11,250,000
Ending Balance, weighted average exercise price | $ / shares	$ 0.03

XML

STOCK OPTIONS AND WARRANTS - Summary of Warrants (Details)	9 Months Ended
	Sep. 30, 2016 $ / shares shares
Temporary Equity Disclosure [Abstract]
Beginning Balance, number of shares | shares	2,969,750
Beginning Balance, weighted average exercise price | $ / shares	$ 0.06
Warrants granted and assumed, number of shares | shares	1,661,000
Warrants granted and assumed, weighted average exercise price | $ / shares	$ .02
Warrants expired, number of shares | shares	1,344,750
Warrants expired, weighted average exercise price | $ / shares	$ 0.06
Ending Balance, number of shares | shares	3,286,000
Ending Balance, weighted average exercise price | $ / shares	$ .04

XML

STOCK OPTIONS AND WARRANTS (Details Narrative) - Stock Options Granted 1	9 Months Ended
	Sep. 30, 2016 USD ($) $ / shares shares
Stock Options, Date Granted	Feb. 10, 2016
Stock Options, shares | shares	4,150,000
Stock Options, strick price | $ / shares	$ 0.02
Stock Options, expected life	3 years
Stock Options, value | $	$ 99,167

XML

NOTES PAYABLE (Details Narrative) - USD ($)	6 Months Ended	9 Months Ended		10 Months Ended	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Mar. 31, 2015	Dec. 31, 2013	Jan. 27, 2016	Dec. 31, 2015	May 19, 2014
Loans payable		$ 2,322,900					$ 1,845,500
Payments on notes payable		$ (25,600)	$ (89,500)
Notes reached maturity		980,000
Debt Executed Agreements		20,000
Notes Payable One
Secured Promissory Notes, max amount offered						$ 33,000
Promissory Notes, Interest Rate						12.00%
Maturity Date		Nov. 06, 2016
Notes Payable Two
Secured Promissory Notes, max amount offered						$ 24,000
Promissory Notes, Interest Rate						10.00%
Maturity Date		May 30, 2016
Notes Payable Three
Maturity Date		Feb. 15, 2016
Thirteen Notes Payable
Secured Promissory Notes, max amount offered	$ 326,000		$ 326,000
Promissory Notes, Interest Rate	9.00%		9.00%
Promissory Notes, Proceeds	$ 326,000
Promissory Notes, Due	2 years
Five Notes Payable
Promissory Notes, Interest Rate	9.00%		9.00%
Promissory Notes, Proceeds			$ 131,000
Promissory Notes, Due			2 years
Twenty Seven Notes Payable
Financing Plan Approved				May 19, 2014
Secured Promissory Notes, max amount offered								$ 1,000,000
Promissory Notes, Interest Rate								9.00%
Promissory Notes, Proceeds				$ 1,000,000
Promissory Notes, Due				2 years
Twenty Four Notes Payble
Financing Plan Approved					May 22, 2013
Secured Promissory Notes, max amount offered					$ 1,000,000
Promissory Notes, Interest Rate					9.00%
Promissory Notes, Proceeds					$ 1,000,000
Promissory Notes, Due					2 years

XML

RELATED PARTY TRANSACTIONS (Details Narrative)	9 Months Ended
	Sep. 30, 2016 USD ($)
Related Party Transactions [Abstract]
Due to Related Party	$ 28,469
Officer Advanced	$ 18,700

XML

CONVERTIBLE NOTES PAYABLE - Schedule of Conversions of Stock (Details) - USD ($)	Sep. 30, 2016	Dec. 31, 2015	Jul. 28, 2015
Convertible Notes Payable	$ 1,278,813	$ 1,205,576
Total Net of Unamortized Discount	(41,921)	(166,969)
Convertible Note 3
Convertible Note Payable			$ 47,500
Unamortized debt discount			(19,497)
Total Net of Unamortized Discount			$ 28,003
Convertible Note 10
Convertible Note Payable	53,404
Unamortized debt discount	(24,222)
Total Net of Unamortized Discount	29,182
Convertible Note 9
Convertible Note Payable	15,000
Unamortized debt discount	(13,719)
Total Net of Unamortized Discount	1,281
Convertible Note 8
Convertible Note Payable	20,000
Unamortized debt discount	(9,699)
Total Net of Unamortized Discount	10,301
Convertible Note 7
Convertible Note Payable	38,000
Unamortized debt discount	(12,044)
Total Net of Unamortized Discount	25,956
Convertible Note 6
Convertible Note Payable	0
Unamortized debt discount	0
Total Net of Unamortized Discount	0
Convertible Note 5
Convertible Note Payable	0	25,000
Unamortized debt discount	0	(15,104)
Total Net of Unamortized Discount	0	9,896
Convertible Note 4
Convertible Note Payable	135,000	135,000
Unamortized debt discount	(62,763)	(106,908)
Total Net of Unamortized Discount	72,207	28,092
Convertible Note 3
Unamortized debt discount
Convertible Note 2
Convertible Note Payable	1,000,000	1,000,000
Unamortized debt discount	111,110	111,110
Total Net of Unamortized Discount	1,111,110	1,111,110
Convertible Note 1
Convertible Note Payable	28,476	28,476
Total Net of Unamortized Discount	$ 28,476	$ 28,476

XML

CONVERTIBLE NOTES PAYABLE (Details Narrative) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2016	Sep. 30, 2015	Aug. 31, 2016	Aug. 11, 2016	Feb. 17, 2016	Feb. 01, 2016	Dec. 17, 2015	Jul. 28, 2015
Beneficial conversion feature		$ 155,230
Convertible Note 1
Expiration Date	Jan. 12, 2010
Convertible Note 2
Expiration Date		Jan. 01, 2015
Beneficial conversion feature		$ 111,110
Convertible Note 3
Convertible Notes Payable, Value									$ 47,500
Interest Rate									8.00%
Expiration Date		Apr. 30, 2016
Beneficial conversion feature		$ 44,634
Financing expense		19,497
Payment of Note		72,458
Repayment Penatly		$ 24,958
Convertible Note 4
Expiration Date		Oct. 17, 2017
Beneficial conversion feature		$ 117,535
Financing expense		$ 44,115
Convertible Note 5
Convertible Notes Payable, Value								$ 25,000
Interest Rate								10.00%
Expiration Date		May 17, 2016
Beneficial conversion feature		$ 16,648
Financing expense		$ 16,648
Convertible Note 6
Convertible Notes Payable, Value							$ 25,000
Interest Rate							10.00%
Expiration Date		Jul. 25, 2016
Beneficial conversion feature		$ 21,819
Financing expense		$ 21,819
Convertible Note 7
Convertible Notes Payable, Value							$ 38,000
Interest Rate							10.00%
Expiration Date		Feb. 15, 2017
Beneficial conversion feature		$ 33,164
Financing expense		$ 21,120
Convertible Note 8
Convertible Notes Payable, Value						$ 20,000
Interest Rate						9.00%
Expiration Date		Feb. 17, 2018
Beneficial conversion feature		$ 14,049
Financing expense		$ 4,349
Convertible Note 9
Convertible Notes Payable, Value					$ 15,000
Interest Rate					9.00%
Expiration Date		Aug. 11, 2108
Beneficial conversion feature		$ 14,728
Financing expense		1,009
Convertible Note 10
Convertible Notes Payable, Value				$ 50,000
Interest Rate				10.00%
Beneficial conversion feature		32,121
Financing expense		7,899
Convertible Note One
Convertible Notes Payable, Value	$ 52,476	$ 52,476
Interest Rate	10.00%	10.00%
Option Rights, Price per Share	$ 0.10	$ 0.10
Convertible Note Two
Convertible Notes Payable, Value	$ 1,000,000	$ 1,000,000
Interest Rate	9.00%	9.00%
Convertible Note Four
Convertible Notes Payable, Value			$ 135,000
Interest Rate			9.00%

XML

CONVERTIBLE NOTES PAYABLE RELATED PARTY - Convertible Notes Payable Related Party Disclouser (Details) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Notes to Financial Statements
Convertible Note Payable #1	$ 1,071,593	$ 1,071,593
Unamortized Debt Discount	(41,921)	(166,969)
Convertible Note Payable #2	321,032	321,032
Unamortized Debt Discount	(31,098)	(62,310)
Convertible Note Payable #3	182,083	182,083
Unamortized Debt Discount	(45,558)	(72,881)
Convertible Note Payable #4	106,152	106,152
Unamortized Debt Discount	(24,726)	(35,345)
Convertible Note Payable #5	142,501	142,501
Unamortized Debt Discount	(42,725)	(56,966)
Convertible Note Payable #6	118,126	118,126
Unamortized Debt Discount	(64,885)	(82,610)
Convertible Note Payable #7	40,558	40,558
Unamortized Debt Discount	(24,266)	(30,338)
Convertible Note Payable #8	65,295	65,295
Unamortized Debt Discount	(37,338)	(45,957)
Convertible Note Payable #9	343,687	343,687
Unamortized Debt Discount	(290,456)	(341,703)
Convertible Note Payable #10	3,600
Unamortized Debt Discount	(764)
Convertible Note Payable #11	33,333
Unamortized Debt Discount	(7,781)
Convertible Note Payable #12	192,417
Unamortized Debt Discount	(26,936)
Convertible Note Payable #13	2,000
Unamortized Debt Discount	(970)
Convertible Note Payable #14	3,600
Unamortized Debt Discount	(1,571)
Convertible Notes Payable	$ 1,984,982	$ 1,495,948

XML

CONVERTIBLE NOTES PAYABLE RELATED PARTY (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Beneficial Conversion Feature	$ 155,230
Convertible Notes Payable Related Party 1
Convertible Notes Payable, Value	$ 1,071,593
Due Date	5 years
Interest Rate	10.00%
Common Stock, Fixed Price	$ 0.04
Conversion Feature, number of warrants to purchase for every two shares issued	1
Warrants, Exercise Price	$ 0.06
Conversion Date	3 years
Beneficial Conversion Feature	$ 1,123,078
Financing Expense	125,048
Cash payments to reduce note balance	51,485
Convertible Notes Payable Related Party 2
Convertible Notes Payable, Value	$ 321,032
Due Date	5 years
Interest Rate	10.00%
Common Stock, Fixed Price	$ 0.04
Conversion Feature, number of warrants to purchase for every two shares issued	1
Warrants, Exercise Price	$ 0.06
Conversion Date	3 years
Beneficial Conversion Feature	$ 209,809
Financing Expense	31,212
Cash payments to reduce note balance	3,990
Convertible Notes Payable Related Party 3
Convertible Notes Payable, Value	$ 182,083
Due Date	5 years
Interest Rate	10.00%
Common Stock, Fixed Price	$ 0.03
Conversion Feature, number of warrants to purchase for every two shares issued	1
Warrants, Exercise Price	$ 0.04
Conversion Date	3 years
Beneficial Conversion Feature	$ 182,083
Financing Expense	27,323
Convertible Notes Payable Related Party 4
Convertible Notes Payable, Value	$ 106,153
Due Date	5 years
Interest Rate	10.00%
Common Stock, Fixed Price	$ 0.03
Conversion Feature, number of warrants to purchase for every two shares issued	1
Warrants, Exercise Price	$ 0.04
Conversion Date	3 years
Beneficial Conversion Feature	$ 70,768
Financing Expense	10,619
Convertible Notes Payable Related Party 5
Convertible Notes Payable, Value	$ 142,501
Due Date	5 years
Interest Rate	10.00%
Common Stock, Fixed Price	$ 0.03
Conversion Feature, number of warrants to purchase for every two shares issued	1
Warrants, Exercise Price	$ 0.04
Conversion Date	3 years
Beneficial Conversion Feature	$ 94,909
Financing Expense	14,241
Convertible Notes Payable Related Party 6
Convertible Notes Payable, Value	$ 118,126
Due Date	5 years
Interest Rate	10.00%
Common Stock, Fixed Price	$ 0.025
Conversion Feature, number of warrants to purchase for every two shares issued	1
Warrants, Exercise Price	$ 0.03
Conversion Date	3 years
Beneficial Conversion Feature	$ 118,126
Financing Expense	17,725
Convertible Notes Payable Related Party 7
Convertible Notes Payable, Value	$ 40,558
Due Date	5 years
Interest Rate	10.00%
Common Stock, Fixed Price	$ 0.04
Conversion Feature, number of warrants to purchase for every two shares issued	1
Warrants, Exercise Price	$ 0.05
Conversion Date	3 years
Beneficial Conversion Feature	$ 40,466
Financing Expense	6,072
Convertible Notes Payable Related Party 8
Convertible Notes Payable, Value	$ 65,295
Due Date	5 years
Interest Rate	10.00%
Common Stock, Fixed Price	$ 0.04
Conversion Feature, number of warrants to purchase for every two shares issued	1
Warrants, Exercise Price	$ 0.05
Conversion Date	3 years
Beneficial Conversion Feature	$ 57,439
Financing Expense	8,619
ConvertibleNotesPayable9Member
Convertible Notes Payable, Value	$ 343,687
Due Date	5 years
Interest Rate	10.00%
Common Stock, Fixed Price	$ 0.02
Conversion Feature, number of warrants to purchase for every two shares issued	1
Warrants, Exercise Price	$ 0.02
Conversion Date	5 years
Beneficial Conversion Feature	$ 341,703
Financing Expense	51,247
ConvertibleNotesPayable10Member
Convertible Notes Payable, Value	$ 3,600
Due Date	5 years
Interest Rate	10.00%
Common Stock, Fixed Price	$ 0.02
Conversion Feature, number of warrants to purchase for every two shares issued	1
Warrants, Exercise Price	$ 0.02
Beneficial Conversion Feature	$ 864
Financing Expense	110
ConvertibleNotesPayable11Member
Convertible Notes Payable, Value	$ 33,333
Due Date	5 years
Interest Rate	10.00%
Common Stock, Fixed Price	$ 0.02
Conversion Feature, number of warrants to purchase for every two shares issued	1
Warrants, Exercise Price	$ 0.02
Conversion Date	3 years
Beneficial Conversion Feature	$ 8,401
Financing Expense	620
ConvertibleNotesPayable12Member
Convertible Notes Payable, Value	$ 192,417
Due Date	5 years
Interest Rate	10.00%
Common Stock, Fixed Price	$ 0.02
Conversion Feature, number of warrants to purchase for every two shares issued	1
Warrants, Exercise Price	$ 0.02
Conversion Date	3 years
Beneficial Conversion Feature	$ 28,365
Financing Expense	1,429
ConvertibleNotesPayable13Member
Convertible Notes Payable, Value	$ 2,000
Due Date	5 years
Interest Rate	10.00%
Common Stock, Fixed Price	$ .01
Conversion Feature, number of warrants to purchase for every two shares issued	1
Warrants, Exercise Price	$ .02
Conversion Date	3 years
Beneficial Conversion Feature	$ 1,012
Financing Expense	42
ConvertibleNotesPayable14Member
Convertible Notes Payable, Value	$ 3,600
Due Date	5 years
Interest Rate	10.00%
Common Stock, Fixed Price	$ .01
Conversion Feature, number of warrants to purchase for every two shares issued	1
Warrants, Exercise Price	$ .02
Conversion Date	3 years
Beneficial Conversion Feature	$ 1,571

XML

STOCKHOLDERS DEFICIT (Details Narrative) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Common Stock, Par Value	$ 0.001	$ 0.001		$ 0.001
Common Stock, Shares Authorized	200,000,000	200,000,000		200,000,000
Common Stock, Issued	119,573,969	119,573,969		115,701,969
Gain (Loss) on extinguishment of debt		$ (2,592)	$ (1,840)
Issuance 1
Date of Issuance		Jan. 27, 2016
Common Stock, Shares Issued		100,000
Warrants, Exercise Price	$ 0.02	$ 0.02
Common Stock, Share Value		$ 2,000
Common Stock, Value Per Share		2.00%
Issuance 2
Date of Issuance		Jan. 27, 2016
Common Stock, Shares Issued		200,000
Warrants, Exercise Price	0.07	$ 0.07
Common Stock, Share Value		$ 4,980
Common Stock, Value Per Share		2.49%
Issuance 3
Date of Issuance		Feb. 01, 2016
Common Stock, Shares Issued		400,000
Warrants, Exercise Price	0.02	$ 0.02
Common Stock, Share Value		$ 9,960
Common Stock, Value Per Share		2.49%
Issuance 4
Date of Issuance		Jun. 30, 2016
Common Stock, Shares Issued		72,000
Common Stock, Shares Issued, Debt Settlement, Value		$ 3,600
Gain (Loss) on extinguishment of debt		$ 2,592
Issuance 5
Date of Issuance		Feb. 01, 2016
Common Stock, Shares Issued		250,000
Warrants, Exercise Price	$ 0.02	$ 0.02
Common Stock, Share Value		$ 6,225
Common Stock, Value Per Share		2.49%
Issuance 6
Date of Issuance		Feb. 02, 2016
Common Stock, Shares Issued		400,000
Common Stock, Share Value		$ 9,960
Common Stock, Value Per Share		2.49%
Issuance 7
Date of Issuance		Sep. 13, 2016
Common Stock, Shares Issued		2,500,000
Warrants, Issued	1,000,000	1,000,000
Warrants, Exercise Price	$ .02	$ .02
[custom:StockholderCashInvestment]		$ 25,000

XML

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2014	Apr. 01, 2016
Commitments and Contingencies Disclosure [Abstract]
Operating leases for 2016	$ 8,576
Operating leases for 2017	5,718
Rental expense	$ 32,358	$ 32,619	$ 41,868
Kintari Shares Aquired				8,000,000
Purchase Agreement for Materials Sold				$ 87,720
Annual Royaly Fee Year One				50,000
Annual Royalty Fee Year Two				100,000
Annual Royaly Fee Year Three				$ 150,000
Royalty Percentage for Payments Not Received				25.00%

XML

SUBSEQUENT EVENTS (Details Narrative) - USD ($)

9 Months Ended

Sep. 30, 2016

Oct. 30, 2016

Oct. 11, 2016

Oct. 08, 2016

Due Date of Unsecured Notes

Dec. 31, 2016

Employee Negotiation 1

Re-Negotiation of Contract Date

Oct. 20, 2016

Details of Re-Negotiation

On October 20, 2016, the Company re-negotiated accrued salaries and interest for an employee. Under the terms of the agreement, $18,000 of accrued salaries not previously converted were converted to promissory notes convertible into common stock with a warrant feature. The Company also refinanced $89,340 in notes issued in 2010 and 2011 through the issuance of a the new note. The $111,056 face value promissory note is unsecured, due on December 31, 2016, and bears an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.01 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.02 per share for three years after the conversion date.

Employee Negotiation 2

Re-Negotiation of Contract Date

Oct. 20, 2016

Details of Re-Negotiation

On October 20, 2016, the Company re-negotiated $328,481 in unsecured notes payable for an employee. Under the terms of the original agreement, the promissory note was due on December 31, 2016, bears an interest rate of 10% and at the investor’s option until the repayment date, the note could be converted to shares of the Company’s common stock at a fixed price of $0.04 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.06 per share for three years after the conversion date. Under the modified terms that $328,481 face value note is now due on December 31, 2019, bears an interest rate of 10% and at the investor’s option until the repayment date, the note can be converted to shares of the Company’s common stock at a fixed price of $0.01 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.02 per share for three years after the conversion date.

Employee Negotiation 3

Re-Negotiation of Contract Date

Oct. 20, 2016

Details of Re-Negotiation

On October 20, 2016, the Company re-negotiated $179,678 in unsecured notes payable for an employee. Under the terms of the original agreement, the promissory note was due on December 31, 2016, bears an interest rate of 10% and at the investor’s option until the repayment date, the note could be converted to shares of the Company’s common stock at a fixed price of $0.04 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.06 per share for three years after the conversion date. Under the modified terms that $179,678 face value note is now due on December 31, 2019, bears an interest rate of 10% and at the investor’s option until the repayment date, the note can be converted to shares of the Company’s common stock at a fixed price of $0.01 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.02 per share for three years after the conversion date.

Employee Negotiation 4

Re-Negotiation of Contract Date

Oct. 20, 2016

Details of Re-Negotiation

On October 20, 2016, the Company re-negotiated $58,437 in unsecured notes payable for an employee. Under the terms of the original agreement, the promissory note was due on December 31, 2016, bears an interest rate of 10% and at the investor’s option until the repayment date, the note could be converted to shares of the Company’s common stock at a fixed price of $0.04 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.06 per share for three years after the conversion date. Under the modified terms that $58,437 face value note is now due on December 31, 2019, bears an interest rate of 10% and at the investor’s option until the repayment date, the note can be converted to shares of the Company’s common stock at a fixed price of $0.01 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.02 per share for three years after the conversion date.

Employee Negotiation 5

Re-Negotiation of Contract Date

Oct. 20, 2016

Details of Re-Negotiation

On October 20, 2016, the Company re-negotiated $415,657 in unsecured notes payable for an employee. Under the terms of the original agreement, the promissory note was due on December 31, 2016, bears an interest rate of 10% and at the investor’s option until the repayment date, the note could be converted to shares of the Company’s common stock at a fixed price of $0.04 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.06 per share for three years after the conversion date. Under the modified terms that $415,657 face value note is now due on December 31, 2019, bears an interest rate of 10% and at the investor’s option until the repayment date, the note can be converted to shares of the Company’s common stock at a fixed price of $0.01 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.02 per share for three years after the conversion date.

Unsecured Note 1

Unsecured Note Interest Rate

10.00%

Proceeds from Unsecured Note Issued

$ 5,070

Unsecured Note 2

Unsecured Note Interest Rate

10.00%

Proceeds from Unsecured Note Issued

$ 5,000

Common Stock For Investment

Common Stock Issued

3,333,350

Warrants Issued

166,675

Warrants Exercisable Rate

2.50%

Cash Investment

$ 50,000